

University of Groningen

The AIM2 inflammasome exacerbates atherosclerosis in clonal haematopoiesis

Fidler, Trevor P.; Xue, Chenyi; Yalcinkaya, Mustafa; Hardaway, Brian; Abramowicz, Sandra; Xiao, Tong; Liu, Wenli; Thomas, David G.; Hajebrahimi, Mohammad Ali; Pircher, Joachim

Published in:
 Nature

DOI:
[10.1038/s41586-021-03341-5](https://doi.org/10.1038/s41586-021-03341-5)

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
 Publisher's PDF, also known as Version of record

Publication date:
 2021

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

Fidler, T. P., Xue, C., Yalcinkaya, M., Hardaway, B., Abramowicz, S., Xiao, T., Liu, W., Thomas, D. G., Hajebrahimi, M. A., Pircher, J., Silvestre-Roig, C., Kotini, A. G., Luchsinger, L. L., Wei, Y., Westerterp, M., Snoeck, H-W., Papapetrou, E. P., Schulz, C., Massberg, S., ... Tall, A. R. (2021). The AIM2 inflammasome exacerbates atherosclerosis in clonal haematopoiesis. *Nature*, 592(7853), 296-301. <https://doi.org/10.1038/s41586-021-03341-5>

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.


The AIM2 inflammasome exacerbates atherosclerosis in clonal haematopoiesis

<https://doi.org/10.1038/s41586-021-03341-5>

Received: 28 September 2019

Accepted: 8 February 2021

Published online: 17 March 2021



Trevor P. Fidler¹✉, Chenyi Xue^{2,3}, Mustafa Yalcinkaya¹, Brian Hardaway¹, Sandra Abramowicz¹, Tong Xiao¹, Wenli Liu¹, David G. Thomas¹, Mohammad Ali Hajebrahimi^{4,5}, Joachim Pircher^{4,5}, Carlos Silvestre-Roig^{5,6}, Andriana G. Kotini^{7,8,9,10}, Larry L. Luchsinger¹¹, Ying Wei¹², Marit Westerterp^{1,13}, Hans-Willem Snoeck¹¹, Eirini P. Papapetrou^{7,8,9,10}, Christian Schulz^{4,5}, Steffen Massberg^{4,5}, Oliver Soehnlein^{5,6,14}, Benjamin Ebert^{15,16}, Ross L. Levine^{17,18}, Muredach P. Reilly^{2,3}, Peter Libby¹⁹, Nan Wang^{1,20}✉ & Alan R. Tall^{1,20}✉

Clonal haematopoiesis, which is highly prevalent in older individuals, arises from somatic mutations that endow a proliferative advantage to haematopoietic cells. Clonal haematopoiesis increases the risk of myocardial infarction and stroke independently of traditional risk factors¹. Among the common genetic variants that give rise to clonal haematopoiesis, the *JAK2*^{V617F} (*JAK2*^{VF}) mutation, which increases JAK–STAT signalling, occurs at a younger age and imparts the strongest risk of premature coronary heart disease^{1,2}. Here we show increased proliferation of macrophages and prominent formation of necrotic cores in atherosclerotic lesions in mice that express *Jak2*^{VF} selectively in macrophages, and in chimeric mice that model clonal haematopoiesis. Deletion of the essential inflammasome components caspase 1 and 11, or of the pyroptosis executioner gasdermin D, reversed these adverse changes. *Jak2*^{VF} lesions showed increased expression of AIM2, oxidative DNA damage and DNA replication stress, and *Aim2* deficiency reduced atherosclerosis. Single-cell RNA sequencing analysis of *Jak2*^{VF} lesions revealed a landscape that was enriched for inflammatory myeloid cells, which were suppressed by deletion of *Gsdmd*. Inhibition of the inflammasome product interleukin-1 β reduced macrophage proliferation and necrotic formation while increasing the thickness of fibrous caps, indicating that it stabilized plaques. Our findings suggest that increased proliferation and glycolytic metabolism in *Jak2*^{VF} macrophages lead to DNA replication stress and activation of the AIM2 inflammasome, thereby aggravating atherosclerosis. Precise application of therapies that target interleukin-1 β or specific inflammasomes according to clonal haematopoiesis status could substantially reduce cardiovascular risk.

Atherosclerotic cardiovascular disease (ACVD) is the major cause of death and disability in the developed world³. A large burden of residual ACVD risk remains despite current therapies, including intensive lowering of low-density lipoprotein levels³, which highlights the need for new treatments. In the Canakinumab Antiinflammatory Thrombosis Outcomes Study (CANTOS), inhibition of IL-1 β reduced cardiovascular events, thereby validating the contribution of inflammation to ACVD⁴. However, canakinumab therapy was associated with a small risk of infections and has not been approved for cardiovascular conditions. Thus, a more precise

way to identify patients who may benefit most from anti-inflammatory therapy is required. Clonal haematopoiesis usually arises from somatic mutations in haematopoietic stem and progenitor cells (HSPCs) in one of four genes (*TET2*, *ASXL1*, *DNMT3A* or *JAK2*), which lead to clonal expansion of haematopoietic cells. The prevalence of clonal haematopoiesis increases with age, and it affects more than 10% of people who are over 70 years old⁴. Although clonal haematopoiesis conferred an increased risk of haematological malignancies of 0.5–1% per year, this modest increase was not nearly enough to account for the 40% increase in mortality, which

¹Division of Molecular Medicine, Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA. ²Cardiometabolic Precision Medicine Program, Cardiology Division, Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA. ³Irving Institute for Clinical and Translational Research, Columbia University Irving Medical Center, New York, NY, USA. ⁴Medical Clinic I, Department of Cardiology, LMU Klinikum, Ludwig Maximilian University, Munich, Germany. ⁵German Center for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance, Munich, Germany. ⁶Institute for Cardiovascular Prevention (IPEK), LMU Munich, Munich, Germany. ⁷Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA. ⁸Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. ⁹Black Family Stem Cell Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. ¹⁰Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA. ¹¹Department of Medicine, Columbia Center for Human Development, Columbia University Irving Medical Center, New York, NY, USA. ¹²Columbia University, New York, NY, USA. ¹³Department of Pediatrics, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. ¹⁴Department of Physiology and Pharmacology (FyFa), Karolinska Institute, Stockholm, Sweden. ¹⁵Department of Medical Oncology, Dana-Faber Cancer Institute, Boston, MA, USA. ¹⁶Howard Hughes Medical Institute, Dana-Faber Cancer Institute, Boston, MA, USA. ¹⁷Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA. ¹⁸Center for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY, USA. ¹⁹Department of Medicine, Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. ²⁰These authors jointly supervised this work: Nan Wang, Alan R. Tall. ✉e-mail: tpf2103@cumc.columbia.edu; nw30@cumc.columbia.edu; art1@cumc.columbia.edu




Fig. 1 | Increased atherosclerosis in mice with macrophage *Jak2^{VF}* expression and *Jak2^{VF}* clonal haematopoiesis. **a, Immunofluorescence staining of aortic root plaques from mice with *Cx3cr1-creJak2^{VF}* bone marrow. White arrows, *Ki67⁺* nuclei. **b–d**, Quantification of lesion area (**b**), percentage of macrophage nuclei that were *Ki67⁺* (**c**; $n = 18$ control, $n = 21$ *Jak2^{VF}* mice) and necrotic core normalized to lesion area (**d**; $n = 17$ control, $n = 21$ *Jak2^{VF}* mice). **e**, Representative haematoxylin and eosin (H&E) images of aortic root lesions**

was mainly due to ACVD¹. Although studies in mouse models of *Tet2^{-/-}* clonal haematopoiesis have shown an increase in atherosclerosis and increased macrophage inflammation, insights into the underlying mechanisms remain limited^{4,5}. It is unclear whether different variants of clonal haematopoiesis increase atherosclerosis through a common mechanism, and the potential for using clinically relevant anti-IL-1 therapies to treat clonal haematopoiesis has not been assessed.

JAK2^{VF} is a gain-of-function mutation that is associated with myeloproliferative neoplasms (MPNs) and an increased risk of atherothrombotic disease⁶. Although *JAK2^{VF}*-associated MPNs are uncommon, the *JAK2^{VF}* mutation was found in 3.1% of a general European population, most of whom did not have features of MPNs⁷. Hyperlipidaemic mice in which all haematopoietic cells contain heterozygous *Jak2^{VF}* mutations, thus modelling MPN, have increased atherosclerosis, abnormalities in multiple cell lineages and inflammasome activation in splenocytes⁸. However, the mechanisms that link these changes to atherosclerosis, the specific role of the macrophage inflammasome, and the relevance of these findings to the much more prevalent milder form of clonal haematopoiesis and its therapeutic targeting are unclear.

Atherosclerosis in *Jak2^{VF}* mice

To gain insights into these mechanisms, we used an *Mx1*-driven Cre recombinase to generate mice expressing *Jak2^{VF}* (ref. ⁹); this recombinase induces expression of the transgene in HSPCs, thereby modelling the acquisition of mutations in human clonal haematopoiesis. We performed RNA sequencing (RNA-seq) on CD11b⁺ splenic myeloid cells from wild-type or *Ldlr^{-/-}* mice following transplantation of wild-type or *Mx1-creJak2^{VF}* bone marrow. Gene ontology analysis showed that expression of *Jak2^{VF}* was associated with enrichment for genes involved in cellular proliferation, DNA damage repair, and metabolic pathways (Extended Data Fig. 1a, b). A hallmark of the early stage of atherosclerosis is the accumulation of macrophages derived from blood monocytes. Local proliferation of macrophages may sustain the macrophage population in advanced atherosclerotic lesions¹⁰. To determine whether macrophage proliferation was increased in atherosclerotic lesions, we generated transgenic mice in which the expression of *Jak2^{VF}* was controlled by tamoxifen-inducible, macrophage-specific *Cx3cr1-Cre* (*Cx3cr1-cre*

from mice with *Jak2^{VF}* clonal haematopoiesis. Scale bar, 200 µm. **f**, Lesion area for mice in **e** ($n = 19$ mice). **g**, Immunofluorescence staining of aortic roots. Arrows, *Ki67⁺* nuclei; yellow dashed lines, lesions. Scale bar, 50 µm. **h**, Increased CD45.2 cells in *Jak2^{VF}* lesions relative to blood monocytes ($n = 18$ control, $n = 15$ *Jak2^{VF}* mice). **i**, Percentage *Ki67⁺* CD45.1 or CD45.2 cells in lesions ($n = 18$ control, $n = 14$ *Jak2^{VF}* mice). Mean \pm s.e.m.; two-tailed *t*-test (**b–d**, **f**), two-way ANOVA with Bonferroni multiple comparison (**h**, **i**).

Jak2^{VF}). After 15 weeks on a Western-type diet, tamoxifen-treated *Ldlr^{-/-}* mice transplanted with *Cx3cr1-creJak2^{VF}* bone marrow displayed increased lesion areas, proliferation of macrophages and formation of necrotic cores (Fig. 1a–d, Extended Data Fig. 2a). The *Jak2^{VF}* allele burden increased in blood monocytes without any change in blood cell counts or plasma cholesterol (Extended Data Fig. 2b, c). By contrast, *S100A8-creJak2^{VF}* mice, in which *Jak2^{VF}* expression is increased specifically in neutrophils (Extended Data Fig. 2d, e), showed no changes in plasma cholesterol, plaque area or morphology (Extended Data Fig. 2f–k). These findings indicate that expression of *Jak2^{VF}* specifically in macrophages drives their proliferation and fosters the formation of necrotic cores.

To study the link between CVD risk and *Jak2^{VF}*-clonal haematopoiesis, we generated chimeric *Ldlr^{-/-}* mice with a mixture of bone marrow from *Mx1-creJak2^{VF}* mice (CD45.2⁺, 20%) and wild-type mice (CD45.1, 80%) or from CD45.2 wild-type mice (20%) and CD45.1 wild-type mice (80%) (Extended Data Fig. 3a). The *Jak2^{VF}* burden in blood cells, blood cell counts, and plasma cholesterol did not change substantially during the study (Extended Data Fig. 3b–l). *Jak2^{VF}* chimeric mice displayed a twofold increase in lesion area (Fig. 1e, f). Although *Jak2^{VF}* monocytes made up only about 30% of the circulating population, *Jak2^{VF}* macrophages comprised about 60% of aortic root macrophages (Fig. 1g, h). In part this may reflect increased expression of integrins in *Jak2^{VF}* blood leukocytes¹¹ leading to increased binding to endothelium over plaques⁸; indeed, bead trapping studies demonstrated increased entry of *Jak2^{VF}* monocytes into lesions (Extended Data Fig. 4a, b). However, *Jak2^{VF}* (CD45.2⁺) macrophages exhibited increased markers of proliferation, indicating that macrophage replication in plaques also contributes to the enrichment of *Jak2^{VF}* macrophages (Fig. 1i, Extended Data Fig. 4c). Notably, CD45.1 macrophages within the same lesions, which encountered a similar milieu to CD45.2⁺ (*Jak2^{VF}*) cells, showed no increase in proliferation. Flow cytometry of plaque leukocytes also showed both increased incorporation of 5-ethynyl-2'-deoxyuridine (EdU) and an increased fraction of CD45.2 cells in the G2M phase of the cell cycle (Extended Data Fig. 4d, e). Consistently, mice with *Jak2^{VF}* Confetti bone marrow¹² (in which haematopoietic cells express one of several fluorescent proteins in a stochastic manner) showed increased expansion of haematopoietic cell clones in lesions compared to controls (Extended Data Fig. 4f, g, Supplementary Videos 1, 2). Thus, the




Fig. 2 | Inflammation promotes macrophage proliferation and features of plaque instability in mice with *Jak2^{VF}* bone marrow.

a, Immunofluorescence images of aortic root plaques. Arrows, Ki67⁺ nuclei. Scale bar, 50 μm. **b**, Percentage Ki67⁺ cells in lesions. **c**, Macrophage number normalized to total cells in lesions ($n = 8$ mice (**b, c**)). **d**, Necrotic core area ($n = 9$ control, $n = 8$ *Casp1/11^{-/-} *Jak2^{VF}* and *Jak2^{VF} Casp1/11^{-/-}* mice). **e**, Cap thickness ($n = 8$ mice). **f**, Lesion area ($n = 9$ control, $n = 8$ *Casp1/11^{-/-} *Jak2^{VF}* and *Jak2^{VF} Casp1/11^{-/-}* mice). **g**, Immunofluorescence staining of aortic root lesions from mice with *Jak2^{VF}* clonal haematopoiesis. Arrows, pYH2AX⁺ nuclei. Scale bars, 100 μm. **h**, pYH2AX⁺MAC2⁺ cells normalized to lesion area ($n = 19$ control, $n = 20$ *Jak2^{VF}* mice). **i**, Representative immunofluorescence staining of aortic**

roots. Yellow dashed lines, lesion. **j**, 8-oxo-deoxyguanosine (8-OHdG) fluorescence intensity normalized to lesion area ($n = 17$ mice). **k**, Representative H&E images of aortic root lesions from mice with *Jak2^{VF}* or *Jak2^{VF} Nlrp3^{-/-}* bone marrow. Yellow dashed lines, necrotic cores. **l, m**, Quantification of lesion area (**l**; $n = 15$ mice) and percentage necrotic core area (**m**; $n = 19$ mice). **n**, Representative H&E images of aortic root lesions from mice with *Jak2^{VF}* ($n = 24$) or *Jak2^{VF} Aim2^{-/-}* ($n = 25$) bone marrow. Yellow dashed lines, necrotic core. **o, p**, Lesion area (**o**) and percentage necrotic core area (**p**). Mean ± s.e.m.; two-tailed *t*-test (**l, m, o, p**); Kruskal–Wallis two-tailed test with Dunn’s comparison (**b, c, e**); one-way ANOVA with Tukey’s post hoc analysis (**d, f**); two-way ANOVA (**e**); two-tailed Mann–Whitney test (**h, j**).

increased proliferation of *Jak2^{VF}* macrophages has a critical cell-intrinsic component that leads to clonal expansion.

Inflammasomes and plaque stability

Atherosclerotic lesions in mice with *Jak2^{VF}* clonal haematopoiesis showed increased macrophage staining for IL-1β (Extended Data Fig. 4h, i), suggesting that inflammasome activation was enhanced. To evaluate the role of inflammasomes in plaque development, we generated *Jak2^{VF}* mice with concurrent deletion of the downstream inflammasome components caspase 1 and 11 (*Jak2^{VF} Casp1/11^{-/-}*). *Jak2^{VF}* mice exhibited an increase in serum levels of the inflammasome product IL-18, and a decrease in cholesterol levels (Extended Data Fig. 5a, b), similar to humans^{2,13}. These changes were partly reversed by *Casp1/11* deficiency, without changes in spleen weight or circulating leukocyte counts (Supplementary Table 1). Deletion of *Casp1/11* in *Jak2^{VF}* mice abrogated increased proliferation of macrophages in lesions (Fig. 2a, b). Moreover, features of plaque stability, including macrophage accumulation, cap thickness, and necrotic core area, improved markedly in mice with *Jak2^{VF} Casp1/11^{-/-}* bone marrow (Fig. 2c–e). Changes in lesion size were not significant (Fig. 2f), possibly because *Jak2^{VF}* mice show a decrease in cholesterol of more than 50% that is partially reversed by

Casp1/11 deficiency. These results show that activation of the inflammasome contributes to increased macrophage proliferation within atherosclerotic lesions and to the promotion of plaque characteristics that are linked to destabilization—a key trigger of the thrombotic complications of atherosclerosis, including myocardial infarction¹⁴.

To understand the mechanisms that link activation of inflammasomes to macrophage proliferation and plaque destabilization, we treated cultured bone marrow-derived macrophages (BMDMs) with M-CSF, a major promoter of macrophage burden in atherosclerotic plaques^{15,16}. *Jak2^{VF}* BMDMs showed increased M-CSF-mediated proliferation, which was completely dependent on IL-1 as it was abolished by the IL-1 antagonist anakinra (Extended Data Fig. 5c). In parallel, the effects of *Jak2^{VF}* and IL-1β signalling converged to increase activity in ERK and AKT signalling pathways, which increase macrophage differentiation and proliferation¹⁷ (Extended Data Fig. 5d–f). Treatment with ERK and AKT inhibitors reversed the increase in proliferation (Extended Data Fig. 5g). *Jak2^{VF}* BMDMs also showed increased CASP1/11-dependent release of lactate dehydrogenase (LDH), which suggests that they were undergoing pyroptotic cell death (Extended Data Fig. 5h). These data suggest that inflammasome activation in *Jak2^{VF}* macrophages increases secretion of IL-1β, which acts on *Jak2^{VF}* macrophages to increase AKT and ERK signalling and thereby leads to both increased proliferation and pyroptotic cell death.




Fig. 3 *Jak2^{VF}* promotes pyroptosis and inflammation in lesions.

a, Representative H&E images of aortic root lesions from mice with *Jak2^{VF}* or *Jak2^{VF}Gsdmd^{-/-}* bone marrow. Dashed lines, necrotic core. Scale bars, 200 μm . **b–d**, Lesion area (**b**), percentage necrotic core area (**c**), and cap thickness (**d**; $n = 14$ *Jak2^{VF}*, $n = 13$ *Jak2^{VF}Gsdmd^{-/-}* mice). **e**, Aortic root lesions were stained for pyH2AX (white arrows). Scale bars, 100 μm . **f**, Quantification of

pyH2AX⁺MAC2⁺ cells ($n = 14$ *Jak2^{VF}*, $n = 13$ *Jak2^{VF}Gsdmd^{-/-}* mice). **g**, Single-cell RNA-seq of plaque cells. UMAP plot of CD45⁺ cells from aortas of *Ldlr^{-/-}* mice with 100% bone marrow of indicated genotypes (control 8 mice pooled; *Jak2^{VF}* 16 mice pooled; *Jak2^{VF}Gsdmd^{-/-}* 8 mice pooled). **h**, Percentage cell populations within clusters. Mean \pm s.e.m.; two-tailed *t*-test (**b–d**, **f**).

Paralleling their increased proliferative capacity, *Jak2^{VF}* macrophages displayed increased glycolysis and mitochondrial respiration (Extended Data Fig. 5i–k), as well as increased mitochondrial reactive oxygen species (ROS) and oxidized DNA (Extended Data Fig. 5l, m). Even though increased mitochondrial ROS could be secondary to inflammasome activation, rather than causative, BMDMs expressing *Jak2^{VF}* and lacking *Casp1/11* showed markedly enhanced cellular accumulation of ROS (Extended Data Fig. 5n, o) thereby situating ROS-dependence upstream of inflammasome activation. Increased mitochondrial ROS can lead to oxidation of DNA and activation of NLRP3 inflammasomes¹⁸ but can also promote damage to nuclear DNA, formation of double-stranded DNA breaks and activation of AIM2 inflammasomes¹⁹. Indeed, immunofluorescence staining of lesions from mice with *Jak2^{VF}* clonal haematopoiesis showed accumulation of oxidized DNA and pyH2AX-positive macrophages (Fig. 2g–j), which suggest the presence of ROS-mediated oxidative DNA damage and replication stress. *Jak2^{VF}* BMDMs showed increases in both polyAdT-mediated AIM2 activation and ATP-mediated NLRP3 inflammasome activation (Extended Data Fig. 6a, b). We also found increased AIM2 and NLRP3 inflammasome activation in human *JAK2^{VF}* macrophages derived from induced pluripotent stem cells (iPS cells) compared to isogenic controls (Extended Data Fig. 6c, d). However, in cultured *Jak2^{VF}* BMDMs, AIM2 protein was increased, whereas NLRP3 was decreased (Extended Data Fig. 6e–g). As *Aim2* is regulated by IFN γ , which is induced by JAK–STAT signalling^{20,21}, we administered IFN γ -neutralizing antibodies to BMDMs. This reversed the increase in *Aim2* expression in *Jak2^{VF}* BMDMs, indicating a direct link between JAK2 gain of function, IFN γ signalling and *Aim2* expression (Extended Data Fig. 6h).

Experiments in mice have established the role of the NLRP3 inflammasome in accelerated atherosclerosis²². However, the above observations

implicated the AIM2 inflammasome in aggravated atherosclerosis resulting from the *Jak2^{VF}* mutation. To assess the respective roles of the NLRP3 and AIM2 inflammasomes²³ in atherosclerosis, we transplanted *Jak2^{VF}Nlrp3^{-/-}* or *Jak2^{VF}Aim2^{-/-}* bone marrow into *Ldlr^{-/-}* mice and fed them a Western-type diet for 12 weeks. Both interventions moderately reduced cholesterol levels (Extended Data Fig. 6i–k). Whereas *Nlrp3* deficiency had no significant effect on the areas of lesions or necrotic cores (Fig. 2k–m), *Aim2* deficiency markedly reduced both (Fig. 2n–p). In multivariate analyses adjusted for plasma cholesterol levels, the effect of *Aim2* on lesion area remained significant. Consistent with cell culture studies, AIM2 expression was increased in *Jak2^{VF}* lesions (Extended Data Fig. 6l, m).

Activation of AIM2 or NLRP3 inflammasomes leads to pyroptotic cell death as a result of CASP1-dependent proteolytic cleavage of gasdermin D (GSDMD). GSDMD N-terminal fragments form pores in the plasma membrane that allow the release of mature IL-1 β and LDH²⁴. To assess the role of GSDMD in *Jak2^{VF}* clonal haematopoiesis, we transplanted bone marrow (either 80% wild-type and 20% *Jak2^{VF}* or 80% wild-type and 20% *Jak2^{VF}Gsdmd^{-/-}*) into *Ldlr^{-/-}* mice. *Gsdmd* deficiency markedly enhanced the *Jak2^{VF}* allele burden in blood, potentially owing to suppression of pyroptosis (Extended Data Fig. 7a–h), with no alteration in cholesterol (Extended Data Fig. 7i). Although there was no change in overall lesion area, there was a decrease in necrotic core formation and a reciprocal increase in cap thickness in *Gsdmd^{-/-}* mice (Fig. 3a–d). In a parallel experiment, we transplanted *Gsdmd^{-/-}* or littermate control bone marrow into *Ldlr^{-/-}* control mice and found no change in lesion area or necrotic core formation (Extended Data Fig. 7j–l). Mice with haematopoietic expression of *Jak2^{VF}* demonstrated a further increase in pyH2ax staining as a result of *Gsdmd* deficiency (Fig. 3e, f), consistent with




Fig. 4 | Effects of anakinra or IL-1 β antibodies on atherosclerotic plaque development. **a**, Representative H&E images of aortic root lesions from mice with 100% *Jak2^{Vf}* bone marrow treated with anakinra. Dashed lines, necrotic core. Scale bar, 200 μm . **b-d**, Lesion area (**b**), percentage necrotic core area (**c**; $n = 24$ *Jak2^{Vf}*, $n = 25$ *Jak2^{Vf}* + anakinra mice), and cap thickness (**d**; $n = 23$ *Jak2^{Vf}*, $n = 25$ *Jak2^{Vf}* + anakinra mice). **e**, Representative immunofluorescence image of aortic roots stained for GFP (*Jak2^{Vf}*-negative cells), MAC2, Ki67 and DAPI. Arrows, Ki67⁺ nuclei. Scale bars, 25 μm . **f**, Percentage Ki67⁺ macrophages ($n = 16$

control, $n = 18$ *Jak2^{Vf}* mice). **g**, Fraction of macrophages in aortic roots normalized to fraction in blood monocytes ($n = 16$ control, $n = 19$ *Jak2^{Vf}* mice). **h-j**, Quantification of aortic root lesion macrophage density (**h**), cap thickness (**i**), and necrotic core area (**j**) ($n = 16$ control, $n = 20$ *Jak2^{Vf}* mice). Mean \pm s.e.m.; two-tailed *t*-test (**b-d**); one-way ANOVA with Tukey's post hoc analysis (**h**); two-way ANOVA with Tukey's post hoc analysis (**f**); Kruskal-Wallis two-tailed test with Dunn's comparison (**g, i, j**).

increased ROS-mediated formation of double-stranded DNA breaks acting upstream of AIM2 inflammasome activation and pyroptosis.

Single-cell RNA-seq

Single-cell RNA-seq studies have uncovered complex changes in immune cell profiles in atherosclerotic lesions in mice, with prominent accumulation of several distinct macrophage populations²⁵. To gain further insights into immune cell populations in atherosclerotic lesions, we carried out single-cell RNA-seq in cells dissociated from the aortae of *Ldlr^{-/-}* mice with haematopoietic expression of *Jak2^{Vf}* or *Jak2^{Vf}Gsdmd^{-/-}*. Clustering visualized on uniform manifold approximation and projection (UMAP) showed 19 distinct cell populations, with a predominance of monocyte and macrophage subsets, but also neutrophils, dendritic cells, T cells and B cells (Fig. 3g, h, Extended Data Fig. 8a, b). Clusters 2 (inflammatory macrophages) and 3 (resident macrophages) were increased in *Jak2^{Vf}* mice, whereas cluster 1 was reduced in both *Jak2^{Vf}* and *Jak2^{Vf}Gsdmd^{-/-}* mice (Extended Data Table 1). Cluster 1 had characteristics of *Trem2^{high}*, foamy non-inflammatory macrophages, consistent with the reduction in LDL cholesterol in *Jak2^{Vf}* mice. A population of inflammatory macrophages (cluster 2) rose in *Jak2^{Vf}* mice and fell with *Gsdmd* deficiency. These cells appeared to be highly inflammatory, with increased expression of multiple chemokines and *Il1r* compared to other clusters (Extended Data Fig. 8a, b, Supplementary Table 2). A formal assessment of cell cycle genes by Seurat analysis revealed a significant excess of expression of G2M-associated genes in *Jak2^{Vf}* cells that appeared especially prominent in clusters 2 and 4 (Extended Data Fig. 8c). *Gsdmd* deficiency reduced all major macrophage populations but increased monocytes in lesional cells (clusters 6–8) (Extended Data Table 1). The clustering analysis also revealed a rare population of macrophages in control mice that were

slightly increased in *Jak2^{Vf}* mice and greatly increased in *Jak2^{Vf}Gsdmd^{-/-}* mice (cluster 13). These macrophages had high expression of *Alox15* and *Saa3*, as well as pro-thrombotic and inflammasome genes (*F5*, *Serpib2*, and *Pycard*). This cluster could represent a distinct population of inflammatory macrophages that cannot complete pyroptosis owing to *Gsdmd* deficiency ('zombie' macrophages). We confirmed the existence of a potentially similar intimal macrophage population by ALOX15 staining of *Gsdmd^{-/-}* lesions (Extended Data Fig. 8d–f). Overall, these studies confirmed an increase in inflammatory, proliferative myeloid populations in *Jak2^{Vf}* lesions that are reduced by *Gsdmd* deficiency, but also revealed complex changes, with a reduced population of non-inflammatory *Trem2^{high}* macrophages and a potentially adverse increase in monocytes and 'zombie' macrophages in *Gsdmd^{-/-}* mice.

Potential therapeutic interventions

To assess the potential of available therapies that could be repurposed for *JAK2^{Vf}*-driven ACVD, we first evaluated the JAK inhibitor ruxolitinib (Rux), which has been approved for treatment of *JAK2^{Vf}*-associated haematological malignancies. Treatment with Rux lowered IL-18 levels but also increased cholesterol levels in patients with MPNs (Extended Data Fig. 9a, b), consistent with earlier findings^{2,26}. Rux treatment similarly reduced IL-18 and increased cholesterol levels in *Ldlr^{-/-}* mice with haematopoietic *Jak2^{Vf}* expression (Extended Data Fig. 9c, d). As found in humans and mouse models of MPN, Rux administration increased mouse body weight and markedly suppressed blood cell counts without altering *Jak2^{Vf}* burden (Extended Data Fig. 9e–l). These changes were associated with the development of slightly smaller atherosclerotic lesions with markedly increased necrotic cores and thinner caps (Extended Data Fig. 9m–q), indicating that Rux therapy promoted lesional necrosis. Rux inhibits both JAK1 and JAK2 and thus could have

broad effects on signalling pathways that are required for cell survival. Rux also reduces oxidative metabolism of glucose in *Jak2^{VF}* cells, leading to depletion of NADPH and glutathione with the potential to promote oxidative cell death²⁷.

To assess the effects of inhibition of the inflammasome product IL-1, we administered the IL-1 receptor antagonist anakinra to *Ldlr^{-/-}* mice with haematopoietic expression of *Jak2^{VF}*. Anakinra had no effect on circulating cell counts or cholesterol, but completely normalized macrophage proliferation and density in early plaques (Extended Data Fig. 10a–f), confirming that IL-1 promotes macrophage proliferation in lesions. Moreover, in mice with *Jak2^{VF}* bone marrow and more advanced atherosclerosis, anakinra reduced the areas of necrotic cores and increased cap thickness in lesions (Fig. 4a–d, Extended Data Fig. 10g). Thus, while not changing overall lesion size, IL-1 antagonism reduced features that have been implicated in instability of human atherosclerotic plaques.

Anakinra inhibits both IL-1 β and IL-1 α ; to inhibit IL-1 β specifically, we administered an antibody that selectively targets mouse IL-1 β to *Ldlr^{-/-}* mice transplanted with 80% wild-type (GFP⁺) and 20% control (GFP⁻) or 80% wild-type (GFP⁺) and 20% *Jak2^{VF}* (GFP⁻) bone marrow (Extended Data Fig. 10h). The anti-IL-1 β antibodies normalized macrophage proliferation in lesions (white Ki67 staining), specifically in *Jak2^{VF}* macrophages (GFP⁻, red staining), and restored *Jak2^{VF}* macrophage burden to levels similar to controls (Fig. 4e–g). Mice with *Jak2^{VF}* clonal haematopoiesis showed no change in plasma cholesterol and modestly increased neutrophil and red cell counts that were not affected by IL-1 β antibody treatment (Extended Data Fig. 10i, Supplementary Table 1). Treatment with antibodies against IL-1 β did not alter *Jak2^{VF}* blood monocyte proliferation (Extended Data Fig. 10j). *Jak2^{VF}* chimeric mice treated with antibodies against IL-1 β showed enhanced features of plaque stability, including decreased macrophage density, decreased necrotic cores and increased fibrous cap thickness (Fig. 4h–j, Extended Data Fig. 10k, l). These reciprocal changes did not result in an overall change in plaque size. Even though mice do not reliably rupture atherosclerotic plaques, changes in macrophage density, necrotic core size, and fibrous cap thickness reflect features that have been implicated in plaque stability in humans¹⁴. These findings parallel the beneficial clinical effects of IL-1 β antibody therapy in CANTOS; in an imaging study, these were not associated with changes in lesion volume²⁸.

Discussion

Our studies suggest that the *Jak2^{VF}* mutation causes cellular metabolic and proliferative changes that lead to DNA oxidative damage, replication stress, AIM2 inflammasome activation and IL-1 β production, which further drives cell proliferation. Increased macrophage proliferation depends on both intrinsic JAK2(VF) function and IL-1 β , which suggests that inflammasome activation creates a feedforward loop to promote proliferation but also leads to pyroptotic cell death. These events lead to an overall increase in the burden of inflammatory macrophages within atherosclerotic lesions but also to increased necrotic core formation (Extended Data Fig. 10m). This is consistent with emerging evidence that inflammasome-dependent GSDMD-mediated formation of membrane pores initially allows secretion of active IL-1 β but eventually leads to pyroptotic cell death²⁹. Even though both NLRP3 and AIM2 inflammasomes could be activated in cultured *Jak2^{VF}* macrophages, the AIM2 inflammasome predominated in promoting lesion formation in vivo, probably reflecting increased expression of AIM2 downstream of JAK/STAT signalling. In atherosclerosis-prone mice with *Tet2* deficiency, increased lesion formation was not associated within macrophage proliferation within plaques and was reversed using an inhibitor of the NLRP3 inflammasome⁵, indicating that distinct mechanisms promote atherosclerosis in clonal haematopoiesis caused by different mutations. Inhibition of IL-1 β or its downstream mediators such as IL-6³⁰ could be particularly effective and potentially broadly beneficial in ACVD associated with clonal haematopoiesis, while targeting of upstream

inflammasome components such as AIM2 or NLRP3 may need to be tailored to the specific genetic factors responsible for clonal haematopoiesis.

Online content

Any methods, additional references, Nature Research reporting summaries, source data, extended data, supplementary information, acknowledgements, peer review information; details of author contributions and competing interests; and statements of data and code availability are available at <https://doi.org/10.1038/s41586-021-03341-5>.

1. Jaiswal, S. et al. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. *N. Engl. J. Med.* **377**, 111–121 (2017).
2. Bick, A. G. et al. Inherited causes of clonal haematopoiesis in 97,691 whole genomes. *Nature* **586**, 763–768 (2020).
3. Benjamin, E. J. et al. Heart disease and stroke statistics—2019 update: a report from the American Heart Association. *Circulation* **139**, e56–e528 (2019).
4. Ridker, P. M. et al. Antiinflammatory therapy with Canakinumab for atherosclerotic disease. *N. Engl. J. Med.* **377**, 1119–1131 (2017).
5. José, J. et al. Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice. *Science* **355**, 842–847 (2017).
6. Landolfi, R. et al. Efficacy and safety of low-dose aspirin in polycythemia vera. *N. Engl. J. Med.* **350**, 114–124 (2004).
7. Cordua, S. et al. Prevalence and phenotypes of *JAK2 V617F* and *calreticulin* mutations in a Danish general population. *Blood* **134**, 469–479 (2019).
8. Wang, W. et al. Macrophage inflammation, erythrophagocytosis, and accelerated atherosclerosis in *Jak2^{V617F}* mice. *Circ. Res.* **123**, e35–e47 (2018).
9. Mullally, A. et al. Physiological *Jak2^{V617F}* expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells. *Cancer Cell* **17**, 584–596 (2010).
10. Robbins, C. S. et al. Local proliferation dominates lesional macrophage accumulation in atherosclerosis. *Nat. Med.* **19**, 1166–1172 (2013).
11. Edelmann, B. et al. *JAK2-V617F* promotes venous thrombosis through $\beta 1/\beta 2$ integrin activation. *J. Clin. Invest.* **128**, 4359–4371 (2018).
12. Snippet, H. J. et al. Intestinal crypt homeostasis results from neutral competition between symmetrically dividing *Lgr5* stem cells. *Cell* **143**, 134–144 (2010).
13. Liu, D. J. et al. Exome-wide association study of plasma lipids in >300,000 individuals. *Nat. Genet.* **49**, 1758–1766 (2017).
14. Hansson, G. K., Libby, P. & Tabas, I. Inflammation and plaque vulnerability. *J. Intern. Med.* **278**, 483–493 (2015).
15. Anderson, K. L. et al. PU.1 and the granulocyte- and macrophage colony-stimulating factor receptors play distinct roles in late-stage myeloid cell differentiation. *Blood* **94**, 2310–2318 (1999).
16. Rajavashisth, T. et al. Heterozygous osteopetrotic (op) mutation reduces atherosclerosis in LDL receptor-deficient mice. *J. Clin. Invest.* **101**, 2702–2710 (1998).
17. Celada, A. et al. The transcription factor PU.1 is involved in macrophage proliferation. *J. Exp. Med.* **184**, 61–69 (1996).
18. Shimada, K. et al. Oxidized mitochondrial DNA activates the NLRP3 inflammasome during apoptosis. *Immunity* **36**, 401–414 (2012).
19. Hu, B. et al. The DNA-sensing AIM2 inflammasome controls radiation-induced cell death and tissue injury. *Science* **354**, 765–768 (2016).
20. Schwartz, D. M. et al. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. *Nat. Rev. Drug Discov.* **16**, 843–862 (2017).
21. Katherine, L. et al. Cloning a novel member of the human interferon-inducible gene family associated with control of tumorigenicity in a model of human melanoma. *Oncogene* **15**, 453–457 (1997).
22. DUEWELL, P. et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. *Nature* **464**, 1357–1361 (2010).
23. Paulin, N. et al. Double-strand DNA sensing Aim2 inflammasome regulates atherosclerotic plaque vulnerability. *Circulation* **138**, 321–323 (2018).
24. Kayagaki, N. et al. Caspase-1 cleaves gasdermin D for non-canonical inflammasome signalling. *Nature* **526**, 666–671 (2015).
25. Zernecke, A. et al. Meta-analysis of leukocyte diversity in atherosclerotic mouse aortas. *Circ. Res.* **127**, 402–426 (2020).
26. Mesa, R. A. et al. Effects of ruxolitinib treatment on metabolic and nutritional parameters in patients with myelofibrosis from COMFORT-1. *Clin. Lymphoma Myeloma Leuk.* **15**, 214–221.e1 (2015).
27. Rao, T. N. et al. *JAK2*-mutant hematopoietic cells display metabolic alterations that can be targeted to treat myeloproliferative neoplasms. *Blood* **134**, 1832–1846 (2019).
28. Choudhury, R. P. et al. Arterial effects of Canakinumab in patients with atherosclerosis and type 2 diabetes or glucose intolerance. *J. Am. Coll. Cardiol.* **68**, 1769–1780 (2016).
29. Evavold, C. L. et al. The pore-forming protein gasdermin D regulates interleukin-1 secretion from living macrophages. *Immunity* **48**, 35–44.e6 (2018).
30. Bick, A. G. et al. Genetic interleukin 6 signaling deficiency attenuates cardiovascular risk in clonal hematopoiesis. *Circulation* **141**, 124–131 (2020).

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© The Author(s), under exclusive licence to Springer Nature Limited 2021

Methods

Mice

All mice used for these studies were female and on a C57BL/6J background. Mice were housed in a specific pathogen-free facility under standard conditions of temperature (about 23 °C) with a 12-h light–dark cycle and food available ad lib (humidity was not noted). Cages and water were changed every 14–21 days. All mouse experiments were conducted in accordance with the Institutional Animal Care and Use Committee of Columbia University guidelines. Mice containing the *Jak2^{617F}* conditional knockin allele were generated as previously described⁹. For transgene expression, *Jak2^{617F}* mice were then crossed to either *Mx1-Cre* (The Jackson Laboratory, B6.Cg-Tg(*Mx1-Cre*)1*Cgn*/J (003556)), B6.Cg-Tg(*S100A8-Cre-EGFP*) (21614), or *Cx3cr1-Cre* (The Jackson Laboratory, B6.129P2(C) *Cx3cr1tm2.1*(*Cre/ERT2*)*Jung*/J (020940)) mice to generate *Mx1-creJak2^{617F}*, *Cx3cr1-creJak2^{617F}*, and *S100A8-creJak2^{617F}*, respectively. For the generation of *Jak2^{617F}Casp1/11^{-/-}* mice, *Mx1-creJak2^{617F}* mice were crossed to *Casp1/11^{-/-}* mice (The Jackson Laboratory, B6N.129S2-Casp1tm1Flv/J (016621)). *Jak2^{617F}Confetti* mice were generated by crossing *Mx1-creJak2^{617F}* mice with *Confetti* mice (The Jackson Laboratory, B6.129P2-Gt(*ROSA*)26*Sortm1*(*CAG-Brainbow2.1*)*Cle*/J mice (17492)). *Jak2^{617F}Aim2^{-/-}* and *Jak2^{617F}Nlrp3^{-/-}* mice were generated by crossing *Mx1-Jak2^{617F}* mice to *Aim2^{-/-}* (The Jackson Laboratory, B6.129P2-*Aim2*Gt(*CSG445*)*Byg*/J) (13144) or *Nlrp3^{-/-}* (The Jackson Laboratory, (B6.129S6-*Nlrp3*tm1Bhk/J) (21302)) mice, respectively. Other animal colonies were purchased from The Jackson Laboratory: wild-type C57BL/6J (000664), *Ldlr^{-/-}* (B6.129S7-*Ldlr*tm1Her/J (002207)), CD45.1 (B6.SJL-Ptprca Pepcb/BoyJ (002014)), and GFP ((C57BL/6-Tg(CAGEGFP)1310sb/LeySopJ (06567)). *Gsdmd* knockout mice were obtained from Genentech. Littermate control mice contained either an allele with *Cre* or the *Jak2^{617F}* transgene, but not both.

Bone marrow transplantation

Bone marrow transplantations (BMT) were conducted as previously described³¹ except that female recipient mice aged 8–12 weeks (C57BL/6J (wild-type) or *Ldlr^{-/-}*) were lethally irradiated once with 10.5 Gy from a caesium gamma source. Within 24 h of irradiation, bone marrow was collected from female donor mice aged 6–15 weeks old with the indicated genotypes and the total bone marrow cell number was quantified. Irradiated mice were randomized to treatment groups and then anaesthetized with isoflurane before receiving 4×10^6 total bone marrow cells each through intravenous (i.v.) injection (100 μ l final volume). Three weeks after BMT, cohorts involving *Mx1-Cre* mice were injected intraperitoneally (i.p.) with 200 μ g/mouse/day polyinosinic:polycytidylic acid (pIpC) twice, with a one-day rest between treatments.

Atherosclerosis studies

For atherosclerosis studies, sample sizes were power based on the assumption of a coefficient of variation of about 25–30% that will enable an 80% chance of detecting a >33% difference in atherosclerosis lesion size, necrotic core formation, and macrophage proliferation with $P < 0.05$. Four weeks after BMT, *Ldlr^{-/-}* recipient mice were fed with a Western-type diet (WTD) (ENVIGO, cat. no. TD.88137) for the indicated time. Isoflurane-anaesthetized mice were repeatedly bled through cheek puncture for serum, complete blood counts, and flow cytometric analysis at the indicated time points. Following diet, aortic roots were collected and fixed with 4% paraformaldehyde for 24 h at 4 °C, then embedded in paraffin (except when CD45.1/2 chimeric mice were used, and for bead recruitment studies, in which case aortic roots were frozen in optimal cutting temperature (OCT) compound).

Histological analysis

Lesion area and necrotic core area. Lesion area was quantified as previously reported³¹. Researchers blinded to genotype processed

paraffinized tissue and sectioned lesions at similar points (mouse to mouse) in the aortic root over a 150- μ m span for a total of six sections (spaced 30 μ m apart). Slides were then stained with H&E and imaged with a Nikon Labophot 2 and Image Pro Plus software (Media Cybernetics version 7.0.0.591). Lesion area was then quantified in a blinded manner and the average of six slides was used to determine lesion area. Similarly, necrotic core area was quantified in a blinded manner using the same six H&E sections. When presented as percentage necrotic core area, total lesion area was used as the denominator.

Cap thickness. Aortic root sections (one per mouse) removed from similar regions (mouse to mouse) were stained with picrosirius red. Cap thickness was measured in the largest lesion on each section at even intervals 2 μ m apart. Then the average thickness of lesion was reported in length units. All lesion analysis was conducted with Fiji software³².

Immunohistochemistry and immunofluorescence

Slides of aortic roots from similar regions (mouse to mouse) were deparaffinized and suspended in a citric acid-based antigen retrieval solution (Vector Laboratories, H3300) and heated under pressure for 20 min. Slides were then cooled, washed 4 times with PBS containing 0.1% Tween 20 (PBST), blocked with 10% goat serum, and incubated with primary antibodies overnight at 4 °C: Ki67 (KI-67 Vector Laboratories VP-K451 1:1,500; KI-67 Abcam ab15580 1:100), IL-1B (Novus NB600-633 1:250), GFP (Abcam ab13970 1:1,000), MAC2 (Cedarlane CL8942AP 1:10,000), ACTA2 (Millipore Sigma C6198 1:500), CD45.2 (Biolegend 109804 1:100), CD45.1 (Biolegend 110750 1:100), DNA/RNA damage (clone 15A3, Abcam ab62623 1:250), γ H2AX (Cell Signaling 9718S 1:500), AIM2 (Abcam ab119791 1:1,000) and/or ALOX15 (Abcam ab244205 1:1,000). Slides were then washed 4 times with PBST, incubated with secondary antibodies (Invitrogen) for 1 h at room temperature, washed 4 times with PBST, and mounted in Prolong Gold antifade reagent with DAPI (Thermo Fisher Scientific). Slides were imaged on a Leica Fluorescent DMI 6000B wide-field microscope. Image analysis was conducted in a blinded manner in Fiji software. For immunohistochemical analysis, slides were incubated with secondary antibodies conjugated to HRP following overnight primary antibody incubation, exposed (Vector Laboratories, SK-4600), and counterstained with haematoxylin. All immunofluorescence analysis was done in a blinded manner using Fiji software.

Ki67. To determine the percentage of Ki67⁺ macrophages in lesions, one slide per mouse was stained and imaged as indicated above. Then Ki67⁺DAPI⁺MAC2⁺ events were recorded as well as all MAC2⁺DAPI⁺ events and the percentage of Ki67⁺ events was calculated. When indicated, CD45.1/2 or GFP were also used in staining to stratify for genotype in the clonal haematopoiesis model. For CD45.1/2 staining, MAC2 staining was not present.

Macrophage density. Macrophage density was determined from one aortic root slide per mouse (from similar regions mouse to mouse) stained for MAC2, DAPI, and ACTA2. Total DAPI⁺MAC2⁺ nuclei were determined per lesion unit area.

Clonal expansions of Confetti cells

To assess clonal expansion of bone marrow-derived macrophages within atherosclerotic lesions, lethally irradiated (2×650 rad with an interval of 4 h) *Ldlr^{-/-}* mice were transplanted with bone marrow cells expressing *Mx1-creJak2^{617F}Confetti* (B6.129P2-Gt(*ROSA*)26*Sortm1*(*CAG-Brainbow2.1*)*Cle*/J (17492) or *Mx1-creConfetti* (5×10^6 cells per mouse i.v.). Three weeks after transplantation, expression of *Cre* recombinase was induced by two intraperitoneal injections of pIpC (200 μ g/mouse/day) followed by feeding with a high-fat diet (ENVIGO, cat. no. TD.88137) for 16 weeks. Immediately after death, the heart and aorta were perfused with 4% methanol-free PFA for 10 min, washed with PBS

and embedded in OCT and frozen at -80°C for 30 min. Frozen samples were cut with a cryotome (CryoStar NX70, ThermoFisher Scientific) into 50- μm sections at aortic valve level, mounted with DAKO mounting medium and imaged within 24 h.

Imaging was performed using a Leica SP8 WLL DIVE FALCON (fast lifetime contrast) system with one- and two-photon excitation, pulsed two-photon excitation from 700 to 1,300 nm. The objective was a HC IRAPO L 25 \times /1.00 W motCORR (WD 2.6 mm). Fluorescence lifetime imaging (FLIM) was used to identify fluorescent macrophages from the highly autofluorescent environment (nuclear GFP (the fourth colour in the confetti model) was not unequivocally identified within lesions due to autofluorescence, and therefore not quantified) in atherosclerotic lesions, and images were analysed using Leica Application Suite X (LAS X) and FIJI (ImageJ) software. Clones were defined as at least two cells of the same colour (of four possible colours of the confetti construct) in close proximity within lesions.

Bead recruitment studies

After 11 weeks WTD feeding, 1- μm latex fluoresbrite green fluorescent microspheres (Polysciences) in PBS were administered i.v. to mice. Twenty-four hours later, mice were bled and bead incorporation into monocytes was determined. Four days later, aortic roots were removed into OCT, frozen and sectioned. Bead accumulation was quantified histologically.

Clonal haematopoiesis model

Chimeric mice were generated by mixing bone marrow from *Jak2^{VF}* or control mice expressing CD45.2 with bone marrow expressing CD45.1 or GFP; 8×10^5 (*Jak2^{VF}* or control): 3.2×10^6 (CD45.1 or GFP) total cells. Bone marrow mixtures were then transplanted into lethally irradiated *Ldlr^{-/-}* mice. WTD feeding was commenced four weeks after BMT for a duration of 7.5 weeks. For IL-1 β antibody experiments, GFP bone marrow instead of CD45.1 bone marrow was used and IL-1 β antibodies or an IgG control (provided by Novartis) were administered subcutaneously weekly as previously described³³.

Flow cytometry analysis of blood cells for fraction CD45.1/2 or GFP positive/negative was conducted throughout the course of study. Cell populations were determined through flow cytometry staining with antibodies to total CD45 (clone 30-F11), CD45.1 (clone A20), CD45.2 (clone 104), GR1 (clone RB6-8C5), CD115 (clone AFS98), CD3 (clone 17A), CD4 (clone GK1.5), CD45R (clone RA3-6B2), and/or CD11b (clone M1/72). At termination of the IL-1 β antibody study, blood monocytes were fixed, permeabilized, stained with 500 nM propidium iodide (Thermo Fisher Scientific, P3566), and analysed by flow cytometry.

Cx3cr1-creJak2^{VF} atherosclerosis study

Mice containing the *Jak2^{VF}* conditional knockin were crossed with mice expressing a tamoxifen-inducible *Cx3cr1-Cre* recombinase (The Jackson Laboratory). Bone marrow from these mice and littermate controls was transplanted into lethally irradiated *Ldlr^{-/-}* mice. Four weeks later, all mice were subjected to a high-cholesterol diet equivalent to ENVIGO (TD.88137) with the addition of 250 mg/kg tamoxifen for 15 weeks. At terminal isolation, blood was collected and pooled from four mice per sample for monocyte and neutrophil isolation with CD115 beads (Miltenyi Biotec, 130-096-354) as well as Ly6G beads (Miltenyi Biotec, 130-120-337), and mRNA was isolated for *Jak2^{V617F}* burden quantification as previously described³⁴. In addition, blood was pooled from two mice and stained for pSTAT5 (Y694) and analysed via flow cytometry. Each spleen was weighed following terminal isolation.

Ruxolitinib atherosclerosis study

Chimeric *Ldlr^{-/-}* mice with 20% *Mx1-Jak2^{VF}* and 80% GFP bone marrow were administered WTD ENVIGO (TD.88137) supplemented with ruxolitinib (2 g/kg)^{35,36} for 12 weeks.

Plasma from patients with MPN treated with ruxolitinib

Plasma was collected from patients with diagnosed with MPN before and at least 3 months after initiation of ruxolitinib therapy at Memorial Sloan Kettering. Samples were obtained with informed consent in accordance with all ethical regulations and were approved by the Institutional Review Board at Memorial Sloan Kettering Cancer Center. IL-18 concentrations were determined via ELISA (MBL 7620). Total plasma cholesterol was determined via Cholesterol E assay (Wako, cat. no. 999-02601).

Anakinra atherosclerosis study

Mx1-creJak2^{VF} and littermate control bone marrow was transplanted into *Ldlr^{-/-}* mice. Four weeks later, WTD was initiated and 10 mg/kg anakinra or saline vehicle was administered intraperitoneally on 6 days per week for 7 weeks (short term) or 12 weeks (long term) to assess features of plaque stability.

CD11b⁺ splenocyte isolation

Freshly collected spleens were filtered through 60- μm cell filters with pressure in red blood cell lysis buffer (Biolegend). Filtered cells were then centrifuged at 800g for 10 min, suspended in MACs buffer (0.5% BSA, 2 mM EDTA, PBS, pH 7.4), filtered once more and centrifuged again. Cells were incubated with CD11b conjugated beads (Miltenyi Biotec, 130-049-601) for 20 min at 4°C , washed with MACs buffer (PBS, 0.1% BSA, 2 mM EDTA), and filtered through 60- μm cell filters. Cells were then used for the indicated assays.

Bone marrow derived macrophage cultures

Bone marrow was flushed from hindlimbs with Hanks balanced salt solution (HBSS) and filtered in 60- μm cell filters on ice. Cells were centrifuged at 800g for 10 min at 4°C and suspended in DMEM with 10% FBS and 20% L-cell medium (LCM). Bone marrow cells were then incubated in non-tissue culture treated flasks for 5 days, quantified, and plated into new dishes overnight for the indicated assays.

Bulk cell RNA-seq

CD11b⁺ splenocytes were isolated from wild-type recipient mice 11 weeks after BMT. For hypercholesterolemia experiments, BMT was conducted in *Ldlr^{-/-}* mice, four weeks after which a WTD was administered and sustained for seven weeks. Following WTD, mice were killed and CD11b⁺ splenocytes were collected and isolated into TRIzol reagent (Thermo Fisher Scientific). Aortic roots were also removed. RNA was isolated with RNeasy kits (Qiagen) and RNA-seq experiments were conducted as previously described³⁷ on a NexSeq 500 (illumina). Genes were considered differentially expressed if they were significant at 5% false discovery rate (FDR) by DESeq2 and were at least twofold different in average reads per kilobase of transcript per million mapped reads (RPKM). Gene ontology analysis was conducted using the PANTHER database³⁸. Extended Data Fig. 1 displays RNA-seq data. All data have been deposited into a public repository.

ROS analysis

BMDMs were plated into 96-well plates and stained with 3 μM MitoSOX (Thermo Fisher Scientific, M36008) for 20 min. Cells were then washed and suspended in DMEM with 1 mM sodium pyruvate and analysed using a SpectraMax M2 (Molecular Devices). Data were normalized to cell number.

For quantification of oxidized mitochondrial DNA, BMDMs were collected and mitochondria isolated using a microcentrifuge kit (Thermo Fisher Scientific, 89874). Mitochondrial DNA was then isolated using AllPrep DNA/RNA Mini Kit (QIAGEN). Isolated mitochondrial DNA was normalized based on DNA content and analysed for 8-hydroxy 2-deoxyguanosine through ELISA (Abcam, ab201734).

Article

BMDMs were incubated with 5 μM 2',7'-dichlorodihydrofluorescein diacetate (H₂DCFDA) (Thermo Fisher Scientific, cat. no. D399) for 30 min in HBSS. BMDMs were then washed, resuspended in DMEM, and analysed on a SpectraMax M2; relative fluorescent units (RFU) were calculated and the data were normalized to cell number. BMDMs were incubated with 5 μM CellROX (Thermo Fisher Scientific, C10422) for 30 min in HBSS. Cells were then washed and suspended in DMEM, and RFU was determined with data normalized to cell number.

Human iPS cell generation and macrophage differentiation

JAK2(V617F) and isogenic JAK2 wild-type iPS cells were generated from peripheral blood mononuclear cells of a patient with primary myelofibrosis, obtained from the Hematological Malignancies Tissue Bank of Mount Sinai with informed consent under a protocol approved by a Mount Sinai Institutional Review Board, using Sendai virus reprogramming, as previously described³⁹. iPS cells were cultured on mitotically inactivated mouse embryonic fibroblasts with human embryonic stem cell medium supplemented with 6 ng/ml FGF2, as previously described³⁹. Haematopoietic lineage specification was performed following a previously described spin-embryoid body-based protocol to generate haematopoietic progenitor cells through a haemogenic endothelium intermediate³⁹. On day 10, the cells were transferred to macrophage differentiation culture consisting of StemPro-34 SFM medium with 1% nonessential amino acids (NEAA), 1 mM L-glutamine and 0.1 mM β -mercaptoethanol (2ME), supplemented with 100 ng/ml macrophage colony-stimulating factor (M-CSF) and 25 ng/ml interleukin 3 (IL-3) for 11 days with medium changes every two days. Following differentiation, macrophages were preincubated with lipopolysaccharide (LPS; 20 ng/ml) for 3 h then incubated with Nigericin at the indicated concentrations, and IL-1 β in the medium was measured using ELISA. For pdAdT administration LPS was not added to the culture medium, and pdAdT was administered in lipofectamine 2000 for 4 h.

Inflammasome activation in BMDMs

NLRP3 inflammasome activation was assessed in BMDMs through treatment with 20 ng/ml LPS (Millipore Sigma, L4391) for three hours, followed by 1mM ATP (Millipore Sigma, A7699). One hour later, the medium was removed and analysed for IL-1 β protein content with ELISA (R&D Systems, DY401). For AIM2 inflammasome activation, BMDMs were treated with 20 ng/ml LPS + pdAdT with lipofectamine 2000 (InvivoGen, cat. no. tlr1-patn) for 6 h. Medium was then collected and IL-1 β protein content measured with ELISA. NLRP3 and AIM2 protein expression in BMDMs were assessed in naive BMDMs. For *Aim2* mRNA analysis IFN γ -neutralizing antibodies (Biolegend 505848) were incubated with BMDMs for 24 h and harvested into TRIzol. mRNA was isolated with a RNeasy kit (Qiagen) and cDNA was generated using a cDNA synthesis kit (Thermo Fisher Scientific, K1671). qPCR was conducted for *Aim2* (GATTCAAAGTGCAGGTGCGG and TCTGAGGCTTAGCTTGAGGAC) normalized to *M36b4*.

LDH activity

Medium was taken from BMDMs incubated in LCM medium for 7 days and analysed for LDH activity with a CyQUANT LDH Cytotoxicity Assay (Thermo Fisher Scientific, C20301). Data were normalized to cell number at 5 days post incubation.

Blood isolation

Blood from mice was collected at the indicated time points through cheek bleed into EDTA-coated tubes. Blood cell numbers were then quantified with a VetScan HM5 Hematology system (Abaxis). For flow cytometry analysis red blood cells (RBCs) were lysed with RBC lysis buffer, washed in PBS with 0.5% BSA and 2 mM EDTA, then stained with the indicated antibodies.

Serum analysis

Mouse serum was isolated through centrifugation of blood at 12,000g for 10 min at 4 °C. Serum was evaluated for IL-18 through ELISA (MBL International, cat. no. 7625). Total serum cholesterol was determined using a cholesterol E assay (Wako, cat. no. 999-02601).

Immunoblot

Protein lysates from the indicated cell type were suspended in radioimmunoprecipitation assay (RIPA) buffer with protease and phosphatase inhibitors (Thermo Fisher Scientific, 78440). Protein concentrations were quantified with bicinchoninic acid (BCA) analysis (Thermo Fisher Scientific, 23225). Proteins were then loaded into polyacrylamide gels (BioRad) and transferred to nitrocellulose or PDVF membranes, blocked with 5% milk, and then incubated overnight with the indicated primary antibody (Cell Signaling pERK 4370T, ERK 4695T, pAKT 4060S, AKT 4298, AIM2 63660S, or NLRP3 15101) in 5% bovine serum albumin (BSA). Membranes were then washed and incubated with secondary conjugated to HRP, washed again, and then visualized with HRP chemiluminescent substrates (Thermo Fisher Scientific, 34580).

BMDM proliferation

H³-thymidine incorporation assays were conducted on BMDMs incubated with LCM medium for 6 days and plated into 12-well plates with normalized cell counts. After a 6-h adhesion period, cells were washed and suspended in DMEM (no FBS or LCM) with H³-thymidine and the indicated chemicals for 16 h. BMDMs were then washed and collected as previously described¹⁷. Scintillation counts were determined using an LS6500 scintillation counter (Beckman Coulter) and normalized to cell number before H³-thymidine addition.

For ERK and AKT inhibitor studies, 5-bromo-2'-deoxyuridine (BrdU) incorporation into BMDMs was monitored. BMDMs were differentiated and incubated in DMDM without FBS in the presence of 5 μM BrdU for 16 h in the presence of 100 ng/ml M-CSF and 500 nM afuresertib or 500 nM FR180204 (Cayman Chemical). BrdU incorporation was measured with Roche cell proliferation ELISA and normalized to total cellular DNA (ThermoFisher Quant-iT PicoGreen dsDNA Kit).

BMDM incubation with anakinra

BMDMs were incubated with 75 $\mu\text{g}/\text{ml}$ anakinra for four hours and harvested into TRIzol. mRNA was isolated with an RNeasy kit (Qiagen) and cDNA was generated using a cDNA synthesis kit (Thermo Fisher Scientific, K1671). qPCR was conducted for *Spil* normalized to *M36b4*.

For protein analysis, BMDMs that were incubated in LCM medium for 5 days were washed and suspended in DMEM with anakinra for 12 h. BMDMs were then stimulated with 1 ng/ml recombinant M-CSF (Pepro-Tech, 315-02) for 30 min, and protein was isolated in RIPA buffer with protease and phosphatase inhibitors. Immunoblots were conducted as described above and protein optical density was quantified in Fiji software.

Seahorse

CD11b⁺ splenocytes were collected as described above and suspended in DMEM containing 25 mM glucose, 1 mM pyruvate, and 2 mM glutamate. Thirty thousand cells per well were plated into 96-well seahorse plates, centrifuged, and analysed with a Seahorse XF96 as previously described⁴⁰.

Mitochondrial potential

BMDMs were stained with 100 ng/ml tetramethylrhodamine (TMRM) (Thermo Fisher Scientific, cat. no. I34361) for 20 min in DMEM with LCM. Cells were then washed, brought into solution with cell stripper (Corning, 25-056-Cl), and suspended in DMEM with LCM. Geometric mean fluorescence (Geo. MFI) was then obtained using flow

cytometry. Following an initial reading, 5 μ M carbonyl cyanide 3-chlorophenylhydrazone (CCCP) (Millipore Sigma, C2759) was added to BDMDs and 10 min later a second Geo. MFI was determined. Final Geo. MFI measurements were recorded as Geo. MFI_{initial} – Geo. MFI_{Final}.

Aortic single-cell digest

Following termination of WTD, aortas were isolated, digested with 2.5 mg/ml liberase (Millipore Sigma, LIBTM-RO), 120 U/ml hyaluronidase (Millipore Sigma, H3506), and 160 U/ml DNase I (Millipore Sigma, DN25) for 45 min at 37 °C as previously described³¹.

For qPCR analysis, cells were washed and stained with CD11b-APC, BV786-Ly6G, CD45.1-PE and CD45.2-BV421. Cells were sorted on a BD Influx sorter and isolated directly into TRIzol. qPCR analysis was conducted as described above.

Aortic macrophage proliferation

Ldlr^{-/-} mice with 20% *Jak2*^{VF} or control bone marrow and 80% CD45.1 bone marrow were subjected to a 12-week WTD. Twenty-four hours before cell collection, mice were injected i.p. with 5-ethynyl-2'-deoxyuridine (EdU; 0.1 mg/mouse). Following aortic digest, cells were stained for CD45.1, CD45.2, and CD68 and washed. EdU incorporation was then determined using Click-iT Plus EdU flow cytometry Assay Kit (ThermoFisher C10363). Cells were then stained with propidium iodine (1 μ g/ml), treated with ribonuclease A, then analysed using flow cytometry.

Single-cell RNA-seq

For single-cell RNA-seq (scRNA-seq), after 12 weeks WTD, *Ldlr*^{-/-} mice with control, *Mx1-Jak2*^{VF}, or *Mx1-Jak2*^{VF} *Gsdmd*^{-/-} bone marrow (not in a chimeric model) were killed, and aortas were digested as indicated above, except that necrosulfonamide (20 μ M, Torcis) was supplemented in all media to prevent ex vivo necroptosis and gasdermin D oligomerization. Cell digests were sorted by flow cytometry for DAPI⁺ CD45⁺ events, then run on Genomics scRNA-seq.

Analysis of scRNA-seq data

Fastq files were processed using the Cell Ranger v.3.1.0 pipeline. In brief, reads were aligned to mouse reference genome build mm10 and a mouse transcriptome built on Ensembl 93 annotation. A unique molecular identifier (UMI) count matrix was generated for each sample, followed by cell-calling implemented in Cell Ranger. Downstream analysis was performed using Seurat v.3.1.1⁴¹ in R. The count matrices were filtered to include 1) genes expressed in ≥ 10 cells; 2) cells with ≥ 200 genes expressed; and 3) cells with $\leq 10\%$ reads mapped to mitochondrial genes. Filtering on the maximum number of genes and the maximum number of UMIs per cell was also applied, with slightly different thresholds owing to differences in sequencing depth. A summary of the filtering parameters are provided in Extended Data Table 1. Filtered count matrices were integrated using the SCTransform workflow in Seurat. First, the top 500 variable genes were identified from each sample. Second, the top 1,500 variable genes from the union of variable genes across four samples were selected as integration features. The first 30 dimensions from canonical correlation analysis were used to identify integration anchors. UMAP was conducted using the first 20 principal components. An SNN graph was built on the integrated data with 20 nearest neighbours and 20 dimensions of principal components. Louvain clustering was applied with a resolution parameter of 0.5. To identify differentially expressed genes for each cluster, we first normalized UMI counts by the total number of UMIs in each cell, multiplied the values by 10,000, and then log-transformed the values with a pseudo-count of 1. A model-based analysis of single-cell transcriptomics test was performed on genes that were expressed in $\geq 25\%$ of cells in the cluster tested or in other cells. Fold change ≥ 1.5 and Bonferroni corrected $P < 0.05$ were used to define differentially expressed genes.

Cell-cycle scoring of scRNA-seq data

Cell-cycle scoring analysis was performed in Seurat. A list of cell-cycle markers⁴² was loaded, including 54 G2/M phase genes and 43 S phase genes. The human gene symbols were converted to mouse gene symbols using the biomaRt⁴³ package in R, which successfully converted 52 G2/M phase genes and 40 S phase genes to mouse gene symbols. Each cell was assigned cell phase classification (G2M/G1/S) based on the expression of the above markers.

Flow cytometric analysis

Samples were analysed on a BD LSRFortessa with FACS Software. For sorting, a BD influx sorter was used with FACS Diva software. Gating strategies are provided in Supplementary Figs. 1–4.

Statistics

Statistical analyses were conducted using Excel (Microsoft Office 2019) and GraphPad prism 8. Data presented were mean \pm s.e.m. All measurements were taken from distinct samples unless otherwise noted. When applicable, all statistical test were conducted using two-sided analyses. Data were tested for normality in Prism 8 using a Kolmogorov–Smirnov test. Formal outliers were removed using a Grubb's test (Prism). RNA-seq statistical analysis was conducted as previously described³⁷.

Reporting summary

Further information on research design is available in the Nature Research Reporting Summary linked to this paper.

Data availability

The datasets generated and/or analysed during the current study are available in the Gene Expression Omnibus with the following accession numbers: mouse CD11b⁺ cells for bulk RNA-seq analysis (Extended Data Fig. 1) (GSE163689), mouse CD45⁺ aortic cells for scRNA-seq (GSE163536). All other relevant data are available from the corresponding authors upon reasonable request. Source data are provided with this paper.

Code availability

Gene ontology analysis used PANTHER (<http://www.pantherdb.org/>).

- Westerterp, M. et al. Cholesterol efflux pathways suppress inflammasome activation, NE Tosis, and atherogenesis. *Circulation* **138**, 898–912 (2018).
- Schindelin, J. et al. Fiji: an open-source platform for biological-image analysis. *Nat. Methods* **9**, 676–682 (2012).
- Vromman, A. et al. Stage-dependent differential effects of interleukin-1 isoforms on experimental atherosclerosis. *Eur. Heart J.* **40**, 2482–2491 (2019).
- Mullally, A. et al. Distinct roles for long-term hematopoietic stem cells and erythroid precursor cells in a murine model of Jak2V617F-mediated polycythemia vera. *Blood* **120**, 166–172 (2012).
- Iacobucci, I. et al. Truncating erythropoietin receptor rearrangements in acute lymphoblastic leukemia. *Cancer Cell* **29**, 186–200 (2016).
- Maude, S. L. et al. Efficacy of JAK/STAT pathway inhibition in murine xenograft models of early T-cell precursor (ETP) acute lymphoblastic leukemia. *Blood* **125**, 1759–1767 (2015).
- Thomas, D. G. et al. LXR suppresses inflammatory gene expression and neutrophil migration through cis-repression and cholesterol efflux. *Cell Rep.* **25**, 3774–3785.e4 (2018).
- Thomas, P. D. et al. PANTHER: a library of protein families and subfamilies indexed by function. *Genome Res.* **13**, 2129–2141 (2003).
- Kotini, A. G. et al. Stage-specific human induced pluripotent stem cells map the progression of myeloid transformation to transplantable leukemia. *Cell Stem Cell* **20**, 315–328.e7 (2017).
- Fidler, T. P. et al. Glucose metabolism is required for platelet hyperactivation in a murine model of type 1 diabetes. *Diabetes* **68**, 932–938 (2019).
- Butler, A., Hoffman, P., Smibert, P., Papalex, E. & Satija, R. Integrating single-cell transcriptomic data across different conditions, technologies, and species. *Nat. Biotechnol.* **36**, 411–420 (2018).
- Tirosh, I. et al. Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. *Science* **352**, 189–196 (2016).
- Durinck, S., Spellman, P. T., Birney, E. & Huber, W. Mapping identifiers for the integration of genomic datasets with the R/Bioconductor package biomaRt. *Nat. Protocols* **4**, 1184–1191 (2009).

Article

Acknowledgements Supported by the Leducq Foundation (TNE-18CVD04) and NIH grants HL-118567, HL-155431, HL-148071, HL-137663, CA108671, CA008748, HL-080472, HL-134892. T.P.F. was supported by a Columbia Clinical and Translational Science Award (CTSA) (TL1-TR-001875), and F32HL151051-01. D.G.T. was supported by F30HL137327. E.P.P. is supported by the US National Institutes of Health (NIH) grants R01HL137219 and R01CA225231, by the New York State Stem Cell Board, and by a Scholar Award from the Leukemia and Lymphoma Society (LLS). C.S. and S.M. were supported by the German Research Foundation (DFG), CRC 1123, grants A07 (C.S.) and B06 (S.M.), as well as the DZHK (German Centre for Cardiovascular Research) and the BMBF (German Ministry of Education and Research) (grant 81Z0600204 to C.S.). We thank M. Gonzalez Pisfil, S. Dietzel and the Core Facility Bioimaging at the Biomedical Center, Ludwig Maximilian University, Planegg-Martinsried, Germany, for technical support. M.W. was supported by a Rosalind Franklin Fellowship from the University Medical Center Groningen and by Netherlands Organization of Scientific Research VIDI grant 91715.350. Research reported in this publication was performed in the CCTI Flow Cytometry Core, supported in part by the Office of the Director, National Institutes of Health under awards S1ORR027050 and S1OOD020056. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Images were collected and/or image processing and analysis for this work was performed in the Confocal and Specialized Microscopy Shared Resource of the Herbert Irving Comprehensive Cancer Center at Columbia University, supported by NIH grant P30 CA013696.

Author contributions T.P.F. designed and performed experiments, analysed data and wrote the manuscript. C.X. aided in the design of scRNA-seq studies and conducted scRNA-seq analysis. M.Y. and B.H. aided in mouse studies, immunohistochemistry and analysis of data. S.A. and T.X. processed tissue and conducted histology experiments and analysis. W.L. aided in mouse studies. D.G.T. designed and conducted RNA-seq analysis of CD11b cells. M.A.H., J.P., C.S., and S.M. designed, conducted, and analysed data from studies of Confetti mice. C.S.-R. and O.S. aided in studies relating to neutrophils. A.G.K. and E.P.P. designed and conducted experiments related to human iPS-derived macrophages. L.L.L. and H.-W.S. aided in the design and analysis of studies related to metabolism, including Seahorse studies. Y.W. aided in statistical analysis

of data. M.W. provided scientific feedback throughout the project, including specifically designing and conducting studies on wild-type versus *Gsdmd*^{-/-} mice. N.W. designed, performed, and analysed data related to atherosclerosis experiments. B.E., R.L.L. and P.L. provided reagents, designed experiments, and wrote the manuscript. M.P.R. designed experiments and aided in analysis of studies related to scRNA-seq. A.R.T. designed experiments, analysed data, and wrote the manuscript.

Competing interests R.L.L. is on the supervisory board of Qiagen and is a scientific advisor to Loxo, Imago, C4 Therapeutics and Isoplexis, which include equity interest. He receives research support from and consulted for Celgene and Roche and has consulted for Lilly, Janssen, Astellas, Morphosys and Novartis. He has received honoraria from Roche, Lilly and Amgen for invited lectures and from Gilead for grant reviews. P.L. is an unpaid consultant to, or involved in clinical trials for Amgen, AstraZeneca, Esperion Therapeutics, Ionis Pharmaceuticals, Kowa Pharmaceuticals, Novartis, Pfizer, Sanofi-Regeneron, and XBiotech, Inc. P.L. is a member of the scientific advisory board for Amgen, Corvidia Therapeutics, DalCor Pharmaceuticals, IFM Therapeutics, Kowa Pharmaceuticals, Olatec Therapeutics, Medimmune, Novartis, and XBiotech, Inc. P.L.'s laboratory has received research funding in the last two years from Novartis. A.R.T. is a scientific advisory board member for Amgen, Staten Biotech and Fortico Biotech and is a consultant for Janssen, CSL and the Medicines Company. B.E. has research funding from Celgene and Deerfield, and consulting fees from Grail. E.P.P. has received honoraria from Celgene and Merck and research support from Incyte for research not related to this study.



Additional information

Supplementary information The online version contains supplementary material available at <https://doi.org/10.1038/s41586-021-03341-5>.


Correspondence and requests for materials should be addressed to T.P.F., N.W. or A.R.T.

Peer review information Nature thanks Clinton Robbins, Eicke Latz and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.

Reprints and permissions information is available at <http://www.nature.com/reprints>.


a**b**

Extended Data Fig. 1 | Bulk RNA-seq analysis of CD11b⁺ splenocytes. a, b. Gene ontology analysis of CD11b⁺ splenocytes from wild-type (a; n=6 control, n=7 *Jak2^{VF}* mice) and *Ldlr^{-/-}* recipient mice (b; n=6 control, n=4 *Jak2^{VF}* mice) containing bone marrow from control or *Mx1-Jak2^{VF}* transgenic mice.




Extended Data Fig. 2 | Monocyte/macrophage- and neutrophil-specific expression of *Jak2^{VF}*. **a**, Scheme of experimental procedures for atherosclerosis studies in mice with monocyte/macrophage-specific expression of *Jak2^{VF}*. **b**, qPCR analysis of *Jak2^{VF}* mRNA in blood monocytes ($n=4$ samples (3 mice pooled per sample, 12 total mice per genotype)) and neutrophils ($n=5$ (3 mice pooled per sample, 15 total mice per genotype)). **c**, Serum cholesterol levels ($n=14, 18, 19$ control, $n=13, 18, 19$ *Jak2^{VF}* mice for day 21, 56, 83, respectively). **d**, Scheme of experimental procedure for studies of mice with neutrophil-specific expression of *Jak2^{VF}*. **e**, qPCR analysis of *Jak2^{VF}*

mRNA in blood monocytes and neutrophils. Each point indicates four mice pooled together ($n=3$ pooled samples, 12 total mice per genotype). **f**, Serum cholesterol levels. **g-k**, Quantification of lesion area (**g**), percentage necrotic core area (**h**), percentage macrophage area (**i**), percentage collagen area (**j**), and percentage smooth muscle cell (SMC) area (**k**; $n=12$ control, $n=9$ *Jak2^{VF}* mice). Mean \pm s.e.m.; two-tailed Mann-Whitney test (**g**), two-tailed *t*-test (**f, h-k**), two-way ANOVA followed by Bonferroni multiple comparison post hoc test (**b, c, e**).




Extended Data Fig. 3 | *Jak2^{VF}* allele burden and blood cell counts in mice with *Jak2^{VF}* clonal haematopoiesis. a, Experimental design for *Jak2^{VF}* clonal haematopoiesis mice. **b–e**, Fraction CD45.2:CD45.1 (*Jak2^{VF}*/control:CD45.1) in blood monocytes (**b**), all CD45⁺ cells (**c**), neutrophils (**d**), and lymphocytes (**e**); black arrow, induction of *Mx1-cre* ($n = 10, 19, 18, 9, 20$ control, $n = 9, 18, 19, 9, 17$ *Jak2^{VF}* mice, for day -7, 26, 40, 47, 53, respectively). **f–j**, Blood cell counts of

white blood cells (**f**; WBC), lymphocytes (**g**), monocytes (**h**), neutrophils (**i**), and red blood cells (**j**; RBCs) ($n = 17, 19, 10, 21$ control, $n = 17, 16, 10, 13$ *Jak2^{VF}* mice, for day -7, 26, 40, 53, respectively). **k**, Serum cholesterol ($n = 17, 18, 19$ control, $n = 17, 12, 18$ *Jak2^{VF}* mice, for day 26, 40, 53, respectively). **l**, Spleen weight ($n = 19$ mice). Mean \pm s.e.m.; two-tailed Mann-Whitney test (**l**), two-way ANOVA followed by Bonferroni multiple comparison post hoc test (**b–k**).



Extended Data Fig. 4 | *Jak2^{VF}* monocytes/macrophages have increased recruitment and proliferation in lesions. **a**, Representative immunofluorescence images of aortic roots stained for latex beads (green), MAC2 (red), and DAPI (blue). White arrows, beads; scale bars, 100 μ m. **b**, Quantification of beads in lesions. **c**, qPCR analysis of mRNA from CD11b⁺ aortic cells sorted for CD45.1 or CD45.2; *PolE* ($n=9$ control, $n=11$ *Jak2^{VF}* mice). **d**, **e**, CD68⁺ cells isolated from aortas quantified for percentage EdU incorporation (**d**) and S/G2/M phase with propidium iodine staining (**e**; $n=11$ control, $n=9$ *Jak2^{VF}* mice). **f**, Representative images of lesions from mice with *Mx1*-Confetti or *Mx1*-*Jak2^{VF}*-Confetti expression in bone marrow. Cyan, cyan


fluorescent protein (membrane-tethered CFP); yellow, membrane yellow fluorescent protein (cytoplasmic YFP); red, red fluorescent protein (cytoplasmic RFP). Yellow dashed lines, lesion boundary; scale bars, 25 μ m. **g**, Quantification of the number of cells per clone in Confetti lesions ($n=149$ control, $n=82$ *Jak2^{VF}* clones; four mice per group). **h**, Representative immunofluorescence images of aortic roots stained for MAC2 (green), IL-1 β (red), and DAPI (blue). Scale bars, 50 μ m. **i**, Quantification of total IL-1 β fluorescent intensity normalized to area ($n=15$ mice). Mean \pm s.e.m.; two-tailed *t*-test (**b**), two-tailed Mann-Whitney test (**d**, **e**, **g**, **i**), Kruskal-Wallis two-tailed test with Dunn's comparison (**c**).



Extended Data Fig. 5 | See next page for caption.


Extended Data Fig. 5 | IL-1 β promotes increased ERK/AKT-driven proliferation of *Jak2^{VF}* macrophages associated with increased glycolytic metabolism and mitochondrial ROS generation. **a, b**, Quantification of serum IL-18 (**a**; $n = 7$ control, $n = 9$ *Casp1/11^{-/-}*, $n = 9$ *Jak2^{VF}*, $n = 9$ *Casp1/11^{-/-}Jak2^{VF}* mice) and cholesterol (**b**; $n = 16$ control, $n = 11$ *Casp1/11^{-/-}*, $n = 7$ *Jak2^{VF}*, $n = 11$ *Casp1/11^{-/-}Jak2^{VF}* mice) following 12-week WTD. **c**, Macrophage proliferation marked by ³H-thymidine incorporation into BMDMs during 16-h incubations ($n = 4$ biological replicates, replicated twice). **d**, Representative immunoblot analysis of BMDMs co-incubated with anakinra. **e, f**, Densitometric quantification of pERK1/2 (**e**; $n = 4$ control, $n = 5$ control + anakinra, $n = 5$ *Jak2^{VF}*, $n = 4$ *Jak2^{VF}* + anakinra; biological replicates from three mice pooled, representative of two experiments) and pAKT (**f**; $n = 5$ biological replicates from three mice pooled, representative of two experiments). **g**, Incorporation of BrdU into BMDMs co-incubated for 16 h with 100 ng ml⁻¹ M-CSF and the indicated inhibitors ($n = 6$ biological replicates from three mice pooled, $n = 5$ M-CSF + FR180204). **h**, LDH release from non-stimulated BMDMs following

7-day culture ($n = 24$ control, $n = 24$ *Casp1/11^{-/-}*, $n = 22$ *Jak2^{VF}*, $n = 19$ *Jak2^{VF}Casp1/11^{-/-}* biological replicates from three mice repeated four times). **i, j**, Glycolysis rate indicated by the extracellular acidification rate (ECAR) (**i**) and mitochondrial respiration marked by oxygen consumption rate (OCR) (**j**; $n = 15$ control, $n = 18$ *Jak2^{VF}* biological replicates repeated twice). **k**, Mitochondrial potential in CD11b⁺ splenocytes measured by tetramethylrhodamine, methyl ester, perchlorate (TMRM) geometric mean fluorescence intensity (geo. MFI) ($n = 6$ mice). **l**, MitoSOX geo. MFI in BMDMs ($n = 3$ mice). **m**, Quantification of mitochondrial localized 8-OHdG in BMDMs ($n = 6$ mice). **n, o**, Total cellular ROS in BMDMs marked by relative fluorescence units (RFU) of DCFDA (**n**) and Cell ROX (**o**; $n = 6$ biological replicates from three mice pooled). Mean \pm s.e.m.; one-way ANOVA followed by Tukey's post hoc test (**a, b, e, o**), Kruskal–Wallis two-tailed test with Dunn's comparison (**f, h, n**), two-way ANOVA followed by Bonferroni's multiple comparison post hoc test (**c, g, i, j**), two-tailed *t*-test (**k–m**).




Extended Data Fig. 6 | *JAK2^{VF}* macrophages display increased NLRP3 and AIM2 inflammasome activation. **a, b**, IL-1 β was quantified in medium from mouse BMDMs treated with pdAdT for 6 h (**a**) or LPS (20 ng ml⁻¹; **b**) followed by a 1-h incubation with ATP ($n = 6$ biological replicates, representative of five experiments). Vertical *P* values are relative to LPS within the same genotype. **c, d**, IL-1 β release from human iPSC-macrophages stimulated with pdAdT (**c**; $n = 12$ baseline, $n = 6$ treatments biological replicates representative of two experiments) and nigericin (**d**; $n = 6$ biological replicates, representative of two experiments). Vertical *P* values are relative to baseline within the same genotype. **e**, Immunoblot analysis of NLRP3 and AIM2 in protein lysates from BMDMs. **f, g**, Densitometric quantification of AIM2 (**f**) and NLRP3 (**g**; $n = 8$ biological replicates from four mice per group pooled together). **h**, *Aim2* mRNA

expression in BMDMs incubated in the presence of IFN γ -neutralizing antibodies for 24 h ($n = 6$ biological replicates). **i**, Experimental scheme of an atherosclerosis study conducted in mice with *Jak2^{VF}* bone marrow deficient in *Nlrp3* or *Aim2*. **j, k**, Plasma cholesterol following 12-week WTD in *Jak2^{VF} Nlrp3^{-/-}* (**j**; $n = 15$ *Jak2^{VF}*, $n = 19$ *Jak2^{VF} Nlrp3^{-/-}* mice) and *Jak2^{VF} Aim2^{-/-}* mice (**k**; $n = 24$ *Jak2^{VF}*, $n = 25$ *Jak2^{VF} Aim2^{-/-}* mice). **l**, Representative immunofluorescence image of aortic roots stained for DAPI (blue) and AIM2 (magenta). Yellow dashed lines, lesions; scale bars, 50 μ m. **m**, Quantification of AIM2 mean fluorescence intensity in lesions ($n = 16$ control, $n = 18$ *Jak2^{VF}* mice). Mean \pm s.e.m.; two-way ANOVA followed by Tukey's post hoc test (**a–d**), one-way ANOVA followed by Tukey's post hoc test (**h**), two-tailed *t*-test (**j, k**), two-tailed Mann–Whitney test (**f, g, m**).




Extended Data Fig. 7 | Haematological parameters and atherosclerosis in *Ldlr*^{-/-} mice transplanted with *Gsdmd*^{-/-} bone marrow. **a, WBCs; **b**, lymphocytes ($n=14$ *Jak2*^{VF}, $n=13$ *Jak2*^{VF}*Gsdmd*^{-/-} mice); **c**, monocytes ($n=14$ *Jak2*^{VF}, $n=12$ *Jak2*^{VF}*Gsdmd*^{-/-} mice); **d**, neutrophils ($n=14$ *Jak2*^{VF}, $n=13$ *Jak2*^{VF}*Gsdmd*^{-/-} mice); **e**, RBCs ($n=13$ mice). **f-h**, *Jak2*^{VF} burden in blood lymphocytes (**f**), neutrophils (**g**), and monocytes (**h**; $n=14$ *Jak2*^{VF}, $n=13$**

Jak2^{VF}*Gsdmd*^{-/-} mice). **i**, Serum cholesterol ($n=13$ mice). **j**, Representative H&E images of aortic root lesions from *Ldlr*^{-/-} mice with wild-type (WT) or *Gsdmd*^{-/-} bone marrow fed a WTD for 12 weeks. Dashed lines, necrotic core; scale bars 200 μm . **k**, Quantification of lesion area. **l**, Percentage necrotic core area ($n=12$ wild-type, $n=14$ *Gsdmd*^{-/-} mice). Mean \pm s.e.m.; two-tailed *t*-test (**a**, **b**, **d**, **e**, **i**, **k**, **l**), two-tailed Mann-Whitney test (**c**, **f-h**).



Extended Data Fig. 8 | scRNA-seq reveals increased proliferation and inflammatory macrophages. a, Heat map of top five differentially expressed genes enriched in each cluster. **b,** Table showing top ten differentially expressed genes in each cluster with cell annotations (each sample pooled from eight mice). **c,** Cell cycle classification based on cell cycle gene expression using Seurat analysis; one-tailed χ^2 test, $P = 1.415 \times 10^{-10}$ indicates G2M cells enriched in *Jak2^{VF}* lesions. **d,** UMAP plot of cluster 13 enriched *Alox15*. Blue


indicates relative gene expression. **e,** Representative immunofluorescence images of aortic root lesions stained for MAC2 (green), ALOX15 (magenta) and DAPI (blue). White dashed lines, plaque; arrows, ALOX15⁺ cells; scale bars, 50 μ m. **f,** Quantification of ALOX15⁺ cells per aortic root section ($n = 14$ *Jak2^{VF}*, $n = 13$ *Jak2^{VF}Gsdmd^{-/-}* mice). Mean \pm s.e.m.; * $P < 0.05$ with respect to control genotype, two-tailed Mann-Whitney test (f).



Extended Data Fig. 9 | Ruxolitinib reduces IL-18 and increases plasma cholesterol in individuals with MPN and mice with *JAK2^{VF}* mutations.

a, b, Plasma from patients with MPN isolated before and after ruxolitinib (Rux) therapy were analysed for IL-18 (**a**) and total cholesterol (**b**; $n=17$ patients). **c, d**, Serum from mice with chimeric 20% *Jak2^{VF}* bone marrow was analysed for IL-18 (**c**) and total cholesterol (**d**; $n=20$ *Jak2^{VF}*, $n=22$ *Jak2^{VF}* + Rux mice). **e**, Body weight following 12 weeks WTD ($n=19$ *Jak2^{VF}*, $n=20$ *Jak2^{VF}* + Rux mice). **f–j**, Blood counts of WBCs (**f**), lymphocytes (**g**), neutrophils (**h**), monocytes (**i**) and RBCs (**j**; $n=18$ *Jak2^{VF}*, $n=22$ *Jak2^{VF}* + Rux mice). **k, l**, *Jak2^{VF}* burden in blood neutrophils (**k**) and monocytes (**l**; $n=17$ *Jak2^{VF}*, $n=20$ *Jak2^{VF}* + Rux mice).

m, Representative H&E images of aortic root lesions from mice with 20% *Jak2^{VF}* chimeric bone marrow treated with Rux. Dashed lines, necrotic core; scale bars, 200 μm . **n, o**, Quantification of lesion area (**n**; $n=17$ *Jak2^{VF}*, $n=18$ *Jak2^{VF}* + Rux mice) and percentage necrotic core area (**o**; $n=18$ mice). **p**, Representative picrosirius red-stained lesions (black lines indicate cap thickness). Scale bars, 200 μm . **q**, Quantification of cap thickness ($n=18$ mice). Mean \pm s.e.m.; Wilcoxon paired two-tailed test (**a**), two-tailed Student's paired *t*-test (**b**); two-tailed Mann–Whitney test (**c, e–j, n–p**), two-tailed *t*-test (**d**), two-way ANOVA followed by Tukey's post hoc test (**k, l**).



Extended Data Fig. 10 | Inhibition of IL-1 reduces macrophage proliferation and density in plaques. **a**, Terminal serum cholesterol levels in mice on a WTD and treated with anakinra for 7 weeks ($n=9$ control, $n=8$ control + anakinra, $n=7$ $Jak2^{VF}$, $n=9$ $Jak2^{VF}$ + anakinra mice). **b**, Representative images of aortic roots following 7-week administration of anakinra or vehicle. MAC2 (green), phalloidin (cyan), Ki67 (red), DAPI (blue); arrows, Ki67⁺ nuclei; scale bars, 50 μ m. **c-e**, Quantification of percentage Ki67⁺ cells (**c**), macrophage density (**d**) and lesion area (**e**; $n=8$ control, $n=8$ control + anakinra, $n=6$ $Jak2^{VF}$, $n=9$ $Jak2^{VF}$ + anakinra mice). **f**, Serum cholesterol following 12 weeks WTD, related to late lesions in Fig. 4 ($n=24$ $Jak2^{VF}$, $n=25$ $Jak2^{VF}$ + anakinra mice). **g**, Representative picrosirius red-stained lesions from mice treated with anakinra for 12 weeks.

Black lines indicate cap thickness; scale bars, 200 μ m. **h**, Experimental design for $Jak2^{VF}$ clonal haematopoiesis mice using GFP⁺ cells. **i**, Terminal serum cholesterol ($n=18$ control IgG, $n=19$ control IL-1, $n=19$ $Jak2^{VF}$ IgG, $n=17$ $Jak2^{VF}$ IL-1 mice). **j**, G2-M phase monocytes from blood identified with propidium iodine staining ($n=18$ control IgG, $n=20$ control IL-1, $n=18$ $Jak2^{VF}$ IgG, $n=17$ $Jak2^{VF}$ IL-1 mice). **k**, Representative picrosirius red-stained aortic root lesions from mice as in **j**. Black lines indicate cap thickness; scale bars, 200 μ m. **l**, Representative H&E images of aortic roots. Dashed lines, necrotic core; scale bars, 200 μ m. **m**, Overall summary scheme. Mean \pm s.e.m.; one-way ANOVA followed by Tukey's multiple comparison post hoc test (**a**, **c-e**), two-tailed *t*-test (**f**); Kruskal-Wallis two-tailed test with Dunn's comparison (**i**, **j**).

Article

Extended Data Table 1 | Characteristics of scRNA-seq analysis

a

	Control vs. <i>Jak2^{VF}</i>	<i>Jak2^{VF}</i> vs. <i>Jak2^{VF}Gsdmd^{-/-}</i>	Control vs <i>Jak2^{VF}Gsdmd^{-/-}</i>
Cluster 1 Trem2- Like Macrophages	5.9x10 ⁻⁴⁹	6.2x10 ⁻⁵³	0.04
Cluster 2 Inflammatory Macrophages	7.1x10 ⁻⁵	1.6x10 ⁻¹⁶	1.6x10 ⁻³³
Cluster 3 Resident Macrophages	3.5x10 ⁻¹⁵	0.47	2.7x10 ⁻⁹
Cluster 4 Neutrophils	0.17	0.01	6.5x10 ⁻⁶
Cluster 5 Trem2 Like Macrophages	0.96	8x10 ⁻⁴	8.2x10 ⁻⁶
Cluster 6 Monocytes	5.2x10 ⁻⁵	1.3x10 ⁻³	1
Cluster 7 Monocytes	1.9x10 ⁻¹⁵	2.7x10 ⁻⁴⁶	8.6x10 ⁻¹³
Cluster 8 Monocytes	0.01	1.8x10 ⁻²⁰	4.8x10 ⁻¹²
Cluster 13 Inflammatory Macrophages	5.9x10 ⁻⁵	3.0x10 ⁻³⁶	4.6x10 ⁻²³
Cluster 14 Cavity Macrophages	0.15	4.7x10 ⁻⁹	3.8x10 ⁻⁵
Cluster 17 Neutrophils	3.5x10 ⁻³	8.3x10 ⁻³	1

b

Sample	Genotype	Min. # genes	Max. # genes	Max. # UMIs	Max. % mitochondrial reads	# genes	# cells
1	Control	200	4,000	20,000	10	13,399	3,546
2	<i>Jak2^{VF}</i>	200	4,000	20,000	10	13,547	2,592
3	<i>Jak2^{VF}</i>	200	5,000	30,000	10	13,678	1,481
4	<i>Jak2^{VF}Gsd^{-/-}</i>	200	4,000	25,000	10	14,184	2,973

a, scRNA-seq population distribution statistics. Bonferroni-corrected *P* values of two-tailed tests of equal proportions between genotypes in a subset of macrophages, monocytes, and neutrophils. Tests of proportions were conducted for cells assigned to macrophages, monocytes, and neutrophils between each pair of genotypes with the null of equal proportions. **b**, Filtering parameters for *Ldlr^{-/-}* mouse scRNA-seq data. The minimum number of genes, maximum number of genes, maximum number of UMIs, and maximum percentage of reads mapped to mitochondrial genes applied to each cell are shown for each sample. The number of genes and the number of cells after filtering are also listed.

Reporting Summary

Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see [Authors & Referees](#) and the [Editorial Policy Checklist](#).

Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

n/a Confirmed

- The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
- A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
- The statistical test(s) used AND whether they are one- or two-sided
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
- A description of all covariates tested
- A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
- A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
- For null hypothesis testing, the test statistic (e.g. F , t , r) with confidence intervals, effect sizes, degrees of freedom and P value noted
Give P values as exact values whenever suitable.
- For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
- For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
- Estimates of effect sizes (e.g. Cohen's d , Pearson's r), indicating how they were calculated

Our web collection on [statistics for biologists](#) contains articles on many of the points above.

Software and code

Policy information about [availability of computer code](#)

Data collection

StepOneTM Software Applied bioscience, Version 2.2, SoftMax Pro Version 3.022, Lecia Advanced Fluorescence version 2.6.0.7266, BDFacs 1.2.0.142, FACs Diva version 8.01, Image pro plus 7.0.0.591, Leica Application Suite X (LAS X), Seahorse Wave Controller Software 2.4, NexSeq System Suite v2.2.0

Data analysis

Prism version 8, Microsoft Excel version 16.29, Fiji Version 2.0, Flowjo Version 9, R Software 3.2.1, Cell Ranger v3.1.0, R v3.4.3, Seurat v3.1.1, biomaRt v2.34.2, DESeq2 v1.18.1, Leica Application Suite X (LAS X).

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research [guidelines for submitting code & software](#) for further information.

Data

Policy information about [availability of data](#)

All manuscripts must include a [data availability statement](#). This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A list of figures that have associated raw data
- A description of any restrictions on data availability

The datasets generated during and/or analyzed during the current study are available in the Gene Expression Omnibus with the following accession numbers: mouse CD11b+ cells for bulk RNA-Seq analysis Extended Figure 1 [GSE163689], mouse CD45+ aortic cells for scRNA-Seq [GSE163536]. Gene ontology analysis utilized PANTHER (<http://www.pantherdb.org/>). All other relevant data are available from the corresponding authors upon reasonable request. Source data are presented in the manuscript.

Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

Life sciences Behavioural & social sciences Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see [nature.com/documents/nr-reporting-summary-flat.pdf](https://www.nature.com/documents/nr-reporting-summary-flat.pdf)

Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size	For atherosclerosis studies sample size were power based on the assumption of a coefficient of variation of ~25–30% that will enable an 80% chance of detecting a >33% difference in atherosclerosis lesion size, necrotic core formation, and macrophage proliferation below ($p < 0.05$).
Data exclusions	The following samples were excluded: Figure 1h- 3 samples were not recorded due to experimental error, following histological processing frozen aortic roots were too damaged to be imaged. Figure 1i- 4 samples were not recorded due to experimental error, following histological processing frozen aortic roots were too damaged to be imaged. Figure 4f. 2 Samples were omitted because no GFP negative macrophages were present in the sampled regions, thus no percent Ki67+ GFP negative macrophages could be calculated for those samples. Extended Figure 4d. 2 Samples were excluded due to contamination which prevented flow cytometry analysis. Extended Figure 5e. 1 sample was removed based on a Grubbs Outlier test. Extended Figure 9n. one sample was removed based on a Grubbs Outlier test.
Replication	Studies employing mice with atherosclerosis were not replicated, unless shown within this manuscript. These studies were not replicated due to ethical, logistical and financial limitations as this these studies employed large numbers of mice. ScRNA-Seq and Bulk cell RNA-Seq were not replicated due to cost and labor involved in analysis. All In vitro macrophage studies in mice and humans were repeated at least twice with similar results, except Aim2 expression in the presence of interferon gamma neutralizing antibodies, MitoSOX staining, mitochondrial 8-oxo-deoxyguanosine quantification, and TMRM quantification due to limited reagents and animals.
Randomization	All studies were performed with randomization when necessary. All animal groups were randomly assigned prior to treatments or bone marrow transplantation, and again when further interventions were employed. Bone marrow donors for bone marrow derived macrophage studies were randomly selected within-genotype groups. For in vitro studies of bone marrow derived macrophages or Human iPS derived macrophages, cultures were randomly assigned experimental conditions.
Blinding	All data analysis was conducted in a blinded manner. All in vivo experiments were conducted in a blinded manner. In vitro experiments were not blinded due to logistical issues.

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Materials & experimental systems

n/a	Involved in the study
<input type="checkbox"/>	<input checked="" type="checkbox"/> Antibodies
<input checked="" type="checkbox"/>	<input type="checkbox"/> Eukaryotic cell lines
<input checked="" type="checkbox"/>	<input type="checkbox"/> Palaeontology
<input type="checkbox"/>	<input checked="" type="checkbox"/> Animals and other organisms
<input type="checkbox"/>	<input checked="" type="checkbox"/> Human research participants
<input checked="" type="checkbox"/>	<input type="checkbox"/> Clinical data

Methods

n/a	Involved in the study
<input checked="" type="checkbox"/>	<input type="checkbox"/> ChIP-seq
<input type="checkbox"/>	<input checked="" type="checkbox"/> Flow cytometry
<input checked="" type="checkbox"/>	<input type="checkbox"/> MRI-based neuroimaging

Antibodies

Antibodies used	Ki-67 Rabbit Ki-67 Vector Laboratories VP-K451 1:1500 IF Ki-67 Rabbit Ki-67 Abcam ab15580 1:100 IF IL-1B Rabbit IL-1B Novus NB600-633 1:250 IF GFP Chicken GFP Abcam ab13970 1:1000 IF MAC2 Rat MAC2 Cedarlane CL8942AP 1:10000 IF ACTA2 594 Millipore Sigma C6198 1:500 IF CD45.2 Biotin Rat Biolegend 109804 1:250 IF CD45.1 594 Rat Biolegend 110750 1:100 IF
-----------------	---

CD45 APC Rat Biolegend 103112 1:100 IF
 CD11b APC 0.002mg/mL IgG2bK Rat CD11b M1/70 Biolegend 101212 1:100 FC
 CD11b FITC 0.002mg/mL IgG2bK Rat CD11b M1/71 Biolegend 101217 1:100 FC
 CD11b PE 0.002mg/mL IgG2bK Rat CD11b M1/72 Biolegend 101208 1:100 FC
 CD11b BV421 0.002mg/mL IgG2bK Rat CD11b M1/72 Biolegend 101236 1:100 FC
 CD45.1 FITC 0.002mg/mL IgG2a, K Mouse CD45.1 A20 Biolegend 110706 1:100 FC
 CD45.1 PE 0.002mg/mL IgG2a, K Mouse CD45.1 A20 Biolegend 110708 1:100 FC
 CD45.1 BV785 0.002mg/mL IgG2a, K Mouse CD45.1 A20 Biolegend 110743 1:100 FC
 CD45.1 BV421 0.002mg/mL IgG2a, K Mouse CD45.1 A20 Biolegend 110732 1:100 FC
 CD45.1 APC 0.002mg/mL IgG2a, K Mouse CD45.1 A20 Biolegend 110714 1:100 FC
 CD45.2 APC 0.002mg/mL IgG2a, K Mouse CD45.2 104 Biolegend 109814 1:100 FC
 CD45.2 FITC 0.002mg/mL IgG2a, K Mouse CD45.2 104 Biolegend 109806 1:100 FC
 Gr1 FITC 0.002mg/mL IgG2b, K Rat Ly6G/C RB6-8C5 Biolegend 108406 1:100 FC
 Gr1 BV421 0.002mg/mL IgG2b, K Rat Ly6G/C RB6-8C5 Biolegend 108434 1:100 FC
 Gr1 APC 0.002mg/mL IgG2b, K Rat Ly6G/C RB6-8C5 Biolegend 108412 1:100 FC
 CD45.2 BV785 0.002mg/mL IgG2a, K Mouse CD45.2 104 Biolegend 109839 1:100 FC
 CD115 Alexa Fluor 488 0.005mg/mL IgG2a, K Rat CD115 AFS98 Biolegend 135512 1:100 FC
 CD115 PE 0.002mg/mL IgG2a, K Rat CD115 AFS98 Biolegend 135506 1:100 FC
 CD115 BV421 0.002mg/mL IgG2a, K Rat CD115 AFS98 Biolegend 135513 1:100 FC
 CD115 APC 0.002mg/mL IgG2a, K Rat CD115 AFS98 Biolegend 135510 1:100 FC
 CD45.2 PE 0.002mg/mL IgG2a, K Mouse CD45.2 104 Biolegend 109808 1:100 FC
 CD4 FITC 0.002mg/mL IgG2b, K Rat CD4 GK1.5 Biolegend 100406 1:100 FC
 CD4 BV785 0.002mg/mL IgG2b, K Rat CD4 GK1.5 Biolegend 100453 1:100 FC
 CD4 APC 0.002mg/mL IgG2b, K Rat CD4 GK1.5 Biolegend 100412 1:100 FC
 CD3 BV785 0.002mg/mL IgG2b, K Rat CD3 17A2 Biolegend 100232 1:100 FC
 CD3 APC 0.002mg/mL IgG2b, K Rat CD3 17A2 Biolegend 100236 1:100 FC
 CD45R RA3-6B2 Biolegend 103225 1:100 FC
 CD45R APC 0.002mg/mL IgG2b, K Rat CD45R RA3-6B2 Biolegend 103212 1:100 FC
 CD45R BV785 0.002mg/mL IgG2b, K Rat CD45R RA3-6B2 Biolegend 103246 1:100 FC
 Total ERK1/2 Rabbit Total ERK1/2 137F5 Cell Signaling 4695T 28 1:1000 FC
 Total AKT HRP Mouse Total AKT 40D4 Cell Signaling 4298s 2 1:1000 FC
 P-p44/42 ERK Rabbit P-p44/42 ERK D13.14.4E Cell Signaling 4370T 24 1:1000 FC
 pAKT (S473) Rabbit pP-AKT (S473) D9E Cell Signaling 4060s 23 1:1000 FC
 DNA/RNA damage Mouse 15A3 Abcam ab62623 1:250 IF
 pyH2ax Rabbit Cell Signaling 9718S 1:500 IF
 AIM2 Abcam ab119791 1:1000 IF
 ALOX15 Rabbit Abcam ab244205 1:1000 IF
 NLRP3 Rabbit Cell Signaling 15101 1:1000 WB
 AIM2 Rabbit Cell Singaling 63660S 1:1000 WB
 Ultra-LEAF™ Purified anti-mouse IFN-γ Antibody Biolegend 505848 1:5000 Neu

Validation

Antibodies were validated based on information provided by the vendor (see below). Immunohistochemistry experiments utilized appropriate IgG Controls (see Supplemental Figure 2). For western blot analysis AIM2 and NLRP3 antibodies (Cell Signaling 63660S and 15101 respectively) were both validated through western blot of Aim2-/- or Nlrp3-/- BMDM protein lysates.

Antibodies for western blot were validated by Cell Signaling:

pERK 4370- https://www.cellsignal.com/products/primary-antibodies/phospho-p44-42-mapk-erk1-2-thr202-tyr204-d13-14-4e-xp-rabbit-mab/4370?site-search-type=Products&N=4294956287&Ntt=4370t&fromPage=plp&_requestid=2371401

ERK 4695- https://www.cellsignal.com/products/primary-antibodies/p44-42-mapk-erk1-2-137f5-rabbit-mab/4695?site-search-type=Products&N=4294956287&Ntt=4695t&fromPage=plp&_requestid=2371539

pAKT 4060- <https://www.cellsignal.com/products/primary-antibodies/phospho-akt-ser473-d9e-xp-rabbit-mab/4060>

AKT- https://www.cellsignal.com/products/antibody-conjugates/akt-pan-40d4-mouse-mab-hrp-conjugate/4298?site-search-type=Products&N=4294956287&Ntt=4298s&fromPage=plp&_requestid=2371755

Antibodies for flow cytometry were validated by Biolegend:

CD11b 101212- <https://www.biolegend.com/en-us/products/apc-anti-mouse-human-cd11b-antibody-345>

CD45 103112- <https://www.biolegend.com/en-us/products/apc-anti-mouse-cd45-antibody-97>

CD45.1 110706- <https://www.biolegend.com/en-us/products/fitc-anti-mouse-cd45-1-antibody-198>

CD45.2 109814- <https://www.biolegend.com/en-us/products/apc-anti-mouse-cd45-2-antibody-2759>

Gr1108406- <https://www.biolegend.com/en-us/products/fitc-anti-mouse-ly-6g-ly-6c-gr-1-antibody-458>

CD115 135512- <https://www.biolegend.com/en-us/products/alexa-fluor-488-anti-mouse-cd115-csf-1r-antibody-7873>

CD3 100232- <https://www.biolegend.com/en-us/products/brilliant-violet-785-anti-mouse-cd3-antibody-7953>

CD4 100453- <https://www.biolegend.com/en-us/products/brilliant-violet-785-anti-mouse-cd4-antibody-11948>

CD45R 103212- <https://www.biolegend.com/en-us/products/apc-anti-mouse-human-cd45r-b220-antibody-442>

Immunofluorescent Antibodies were obtained and validated from multiple sources.

Ki-67 Abcam ab15580- <https://www.abcam.com/ki67-antibody-ab15580.html>

Ki-67 Vector Laboratories VP-K451-
<https://vectorlabs.com/media/docs/brochures/VectorCatalog2012.pdf>

GFP Abcam ab13970- <https://www.abcam.com/gfp-antibody-ab13970.html>

AIM2 Abcam ab119791- <https://www.abcam.com/aim2-antibody-ab119791.html>

DNA/RNA damage Abcam ab62623- <https://www.abcam.com/dnarna-damage-antibody-15a3-ab62623.html>

ALOX15 Abcam ab244205- <https://www.abcam.com/15-lipoxygenase-1-antibody-epr22138-ab244205.html>

IL-1B Novus NB600-633- https://www.novusbio.com/products/il-1-beta-il-1f2-antibody_nb600-633

MAC2 Cedarlane CL8942AP-<https://www.cedarlanelabs.com/products/detail/cl8942ap?lob=AllProducts>

ACTA2 Millipore Sigma C6198- <https://www.sigmaaldrich.com/catalog/product/sigma/c6198?lang=en®ion=US>

pyH2ax Cell Signaling 9718S- <https://www.cellsignal.com/products/primary-antibodies/phospho-histone-h2a-x-ser139-20e3-rabbit-mab/9718>

CD45.2-Biotin Biolegend 109804- <https://www.biolegend.com/fr-ch/products/biotin-anti-mouse-cd45-2-antibody-5>

CD45.1-594 Biolegend 110750- <https://www.biolegend.com/fr-ch/products/alexa-fluor-594-anti-mouse-cd45-1-antibody-13424>

Ultra-LEAF™ Purified anti-mouse IFN-γ Antibody Biolegend 505848- <https://www.biolegend.com/fr-ch/products/ultra-leaf-purified-anti-mouse-ifn-gamma-antibody-7752>

Animals and other organisms

Policy information about [studies involving animals](#); [ARRIVE guidelines](#) recommended for reporting animal research

Laboratory animals

Experiments were conducted with recipient mice between the age of 8-24 weeks, dependent on the duration of study. All donor mice were female between the age of 6-15 weeks old. All mice used for these studies were on a C57BL/6J background and housed in a specific pathogen free facility under standard conditions of temperature (~23-degrees Celsius) with a 12-hour light/dark cycle, food available ad lib and humidity was not noted. Cages and water were changed every 14-21 days. All animal experiments were conducted in accordance with the Institutional Animal Care and Use Committee of Columbia University. Mice harboring Jak2V617F conditional knockin allele were generated as previously described¹. These mice were then crossed to either Mx1-Cre (The Jackson Laboratory, B6.Cg-Tg(Mx1-cre)1Cgn/J (003556)), B6.Cg-Tg(S100A8 cre,-EGFP) (21614), or Cx3cr1-Cre (The Jackson Laboratory, B6.129P2(C) Cx3cr1tm2.1 (cre/ERT2)Jung/J (020940)) mice. For Jak2VF x Caspase1/11-/- Mx1-Cre Jak2VF, mice were crossed to Caspase1/11-/- mice (The Jackson Laboratory, B6N.129S2-Casp1tm1Flv/J (016621)). Confetti mice were generated by crossing Mx-Cre Jak2VF with B6.129P2-Gt(ROSA)26Sortm1 (CAG-Brainbow2.1)Cle/J (17492) from Jackson laboratory. Jak2VFAim2-/- and Jak2VFNlrp3-/- mice were generated by crossing Mx1-Jak2VF to Aim2-/- (B6.129P2-Aim2Gt(CSG445)Byg/J) (13144) and Nlrp3-/- (B6.129S6-Nlrp3tm1Bhk/J) (21302) mice respectively. Wild-type (WT) (C57BL/6J, 000664) mice, Ldlr-/- (B6.129S7-Ldlrtm1Her/J, 002207), CD45.1 (B6.SJL-Ptprca Pepcb/BoyJ, 002014), and GFP (C57BL/6-Tg(CAGEGFP)1310sb/LeySopJ, (06567) mice were purchased from The Jackson Laboratory. Gasdermin D knockout mice were obtained from Genentech. Littermate control mice contained either an allele with Cre or Jak2VF transgene, but not in combination.

Wild animals

No Wild Animals were used in these studies

Field-collected samples

No field-collected samples were used in these studies

Ethics oversight

All animal experiments were conducted in accordance with the Institutional Animal Care and Use Committee of Columbia University (protocol # AAAS4462)

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Human research participants

Policy information about [studies involving human research participants](#)

Population characteristics

For studies of Ruxolitinib; plasma was collected from patients with diagnosed myeloproliferative neoplasms that were referred to and treated at Memorial Sloan Kettering Cancer Center. Population composition was 10 Male:7 Female, 15/17 White with 2/17 unreported, with an age range of 28-84 years of at the time of plasma isolation and Rux administration. iPS cells were generated from peripheral blood mononuclear cells of a patient with primary myelofibrosis, no other patient characteristics were recorded.

Recruitment

No exclusion criteria were provided for recruitment of patients with myeloproliferative neoplasms. Selection biases may have occurred in referral to Memorial Sloan Kettering Cancer Center or Mount Sinai.

Ethics oversight

This study was approved by Memorial Sloan Kettering Cancer Center Institutional Review Board (protocol #06-107). Studies of iPS macrophages were approved under a protocol approved by a Mount Sinai Institutional Review Board

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Flow Cytometry

Plots

Confirm that:

- The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
- The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
- All plots are contour plots with outliers or pseudocolor plots.
- A numerical value for number of cells or percentage (with statistics) is provided.

Methodology

Sample preparation

CD11b+ splenocytes: Freshly harvested spleens were filtered through 60 μ m cell filters with pressure in red blood cell lysis buffer (Biolegend). Filtered cells were then centrifuged at 800g x 10 minutes, suspended in MACs buffer (0.5% BSA, 2mM EDTA, PBS, pH 7.4), filtered once more and centrifuged again. Cells were incubated with CD11b conjugated beads (Miltenyi Biotec, 130-049-601) for 20 minutes at 4oC, washed with MACs buffer (PBS, 0.1% BSA, 2mM EDTA), and filtered through 60 μ m cell filters. Cells were then used for the indicated assays.

Bone marrow was flushed from hindlimbs with Hanks balanced salt solution (HBSS) and filtered in 60 μ m cell filters on ice. Cells were centrifuged 800g x 10 minutes at 4oC and suspended in DMEM with 10% FBS and 20% L-cell media (LCM). Bone marrow cells were then incubated in non-tissue culture treated flasks for 5 days, quantified, and plated into new dishes overnight for the indicated assays.

Blood from mice was collected at the indicated timepoints through cheek bleed into EDTA coated tubes. Blood cell numbers were then quantified with VetScan HM5 Hematology system (Abaxis, Union City, CA). For flow cytometry analysis red blood cells (RBC) were lysed with (RBC lysis buffer), washed in PBS with 0.5% BSA and 2mM EDTA, then stained with the indicated antibodies.

Aortic Single Cell Digest

Following termination of WTD, aortas were isolated, digested with 2.5mg/mL liberase TM (Millipore Sigma, LIBTM-RO), 120U/mL hyaluronidase (Millipore Sigma, H3506), and 160U/mL deoxyribonuclease I (Millipore Sigma, DN25) for 45 minutes at 37oC as previously described². Following isolation, cells were washed and stained with CD11b-APC, BV786-Ly6G, CD45.1-PE, CD45.2-BV421. Cells were sorted on a BD Influx sorter and isolated directly into TRIzol. qPCR analysis was conducted as described above.

Instrument

BD Fortessa, and BD Influx Sorter

Software

BD Diva and BD FACs

Cell population abundance

BMDMs comprised nearly 100% of cell populations in cultures. CD11b+ cells in aorta comprised ~5-10% of the total cell population. CD11b+ splenocytes comprised ~100% of the CD11b+ bead separated population.

Gating strategy

FSC/SSC to CD11b+
 FSC/SSC to CD115/Gr1 to GFP+/-
 FSC/SSC to CD3/4/45R to GFP+/-
 FSC/SSC to CD45.1 + CD45.2 cells to CD115/Gr1 to CD45.1 vs. CD45.2
 FSC/SSC to CD45.1 + CD45.2 cells to CD3/4/45R to CD45.1 vs. CD45.2
 FSC/SSC to Trigger Pulse Width to DAPI Negative to CD45-BV780 and CD45-APC double positive

- Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.